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1. INTRODUCTION  
 
1.1 The gastrointestinal tract  
 
For a long time the primary function of the gastrointestinal tract (GIT) had simply been 
considered to digest and absorb nutrients and to excrete waste end products [1, 2]. The 
assertion of Josh Billings “a good reliable set of bowels is worth more to a man than any 
quantity of brains” (1818-1875) represents a milestone in the knowledge of the digestive tract. 
Today, the GIT is known to play a central role in general well being and health [3]. With up to 
400 m2, it is not only the largest body area interacting with the environment, but also the 
largest organ of immune defence in the human body [4]. The GIT is a complex, heavily 
populated and diverse ecosystem [5]. The microbial consortium (microbiota) consists of up to 
10 Exponential 14 (10E14) microorganisms (mainly bacteria, but also fungi and protozoa) [6]. 
More than 500 different bacterial species coexist in the human colon. The exact numbers 
remain to be defined since less than 30% of the microorganisms can be cultured with current 
microbiological methods [7, 8]. It is estimated that about 40 species make up 99% of all 
isolated bacteria [9, 10]. Remarkably, these species belong to only eight of the 55 known 
bacterial divisions, with the Firmicutes, Bacteroides and Actinobacteria being the most 
widely represented [11]. Other bacteria that have been identified in high numbers include 
bifidobacteria, lactobacilli, coliforms, methanogens and dissimilatory sulfat-reducing bacteria 
(Figure 1) [7]. 
 
 
Figure 1. Diagrammed representation of the human GIT showing approximate bacterial 
numbers in each region [12].  
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Molecular tools based on 16S ribosomal desoxyribonucleic acid (rDNA) sequence similarities 
such as fluorescent in-situ hybridization (FISH), denaturing and temperature gradient gel 
electrophoresis (DGGE and TGGE), quantitative dot blot hybridization and restriction 
fragment length polymorphism (RFLP) have helped to overcome limitations of conventional 
microbiological plating methods [13-15]. The majority of the intestinal microorganisms have 
a strictly anaerobic metabolism [16]. Their metabolic end-products are short chain fatty acids 
(SCFA), mainly acetate, propionate, butyrate and a variety of other metabolites including 
products such as lactate, pyruvate, ethanol, hydrogen, succinate [5, 17]. SCFA serve as an 
energy source for the mucosal cells or are further metabolized by other bacterial species. The 
composition of the microbiota is affected by many different environmental factors such as 
diet, medication, stress, age and general living conditions [18]. The sequence in which 
bacteria settle in a niche is also determined by other factors, including host genetics, immune 
surveillance, and others [19]. During the birth process and rapidly thereafter, microbes from 
the mother and surrounding environment colonize the gut of the newborn [20]. Initially, 
facultative anaerobic strains such as Escherichia coli (E. coli)  and Enterococcus predominate 
[21, 22] in the neonatal gut. They create a highly reduced environment that promotes the 
colonisation of strict anaerobes, including Bifidobacterium, Bacteroides and Clostridium 
species [21, 23]. Other anaerobes get successively established, resulting in a highly diverse 
and stable microbiota in adult age [24]. Studies have shown that vaginally delivered infants 
acquire Bifidobacterium and Bacteroides species faster than infants delivered by caesarean 
section [25, 26] and have a lower risk to develop atopic diseases [27-29]. Furthermore, 
breastfed infants have higher numbers of bifidobacteria than bottle fed children [30, 31] and 
seem to suffer less frequently from allergic diseases [32-35]. 
Evidence is increasing that the gut microbiota not only modulates the mucosal physiology and 
barrier function but also systemic and inflammatory responses [36, 37], as well as tolerance to 
innocuous antigens [38-40]. However, due to the dynamic complexity of the human 
microbiota, it has been difficult to establish the existence of clear associations between 
specific microbes and health. An understanding of the dynamics and physiologic functions of 
the microbiota is still in its infancy, but progress in biosciences supports the hypothesis that 
beyond providing nutrition, diet may also modulate various functions in the body that are 
relevant to health [41]. Growing knowledge of the gut microbiota and its interactions with the 
immune system has led to the development of special dietary strategies that serve to sustain or 
even improve normal GIT microbiology. Both prebiotics and probiotics are popular 
substances that have been developed to target the GIT microbiota. 
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1.2 Probiotics 
 
The history of probiotics dates back as far as the first intake of fermented milk over 2000 
years ago. In a Persian version of the Old Testament (Genesis 18:8) it states that “Abraham 
owed his longevity to the consumption of sour milk” [42, 43]. However, it was not until early 
in the 20th century that scientists like E. Mechtnikoff and H. Tissier developed the concept of 
what we now know as probiotics [44, 45]. The term “probiotic”, meaning “for life” is derived 
from the Greek language. It was first used by Lilly and Stillwell [46] in 1965 to describe 
“substances secreted by one mircoorganism, which stimulated the growth of another” and thus 
was opposed to the term “antibiotic” [43]. Today probiotics are defined as “live microbial 
feed supplements, which beneficially affect the host by improving its intestinal microbial 
balance” [47].  
 
A microbial strain is defined as probiotic [48], if it is  
- of human origin 
- non-pathogenic (documented clinical safety)  
- resistant to technical processing (shelf-life, stability)  
- resistant to gastric acid, bile salts and pancreatic enzymes 
- able to adhere to intestinal epithelial tissue   
- able to survive and colonize the intestinal tract  
- able to produce antimicrobial substances 
- able to a modulate immune responses (clinically validated and documented health effects).  
 
Probiotics are mainly lactic acid producing bacteria (lactobacilli, lactococci, streptococci, 
enterococci, bifidobacteria) [5] but also some Bacillus species and non-pathogenic yeasts such 
as Saccharomyces (S. boulardii, S. cerevisae) and Aspergillus species. [49]. The most 
common probiotics belong to the genera Lactobacillus (L. casei, L. acidophilus, L. 
rhamnosus, L. plantarum, L. johnsonii, L. reuteri) and Bifidobacterium (B. bifidum, B. lactis, 
B. longum, B. brevis) and new strains are being isolated regularly [50].  
The health effects attributed to probiotics are numerous and there is some evidence that 
probiotics are beneficial for the treatment and prevention of certain diseases [51, 52]. For 
example, two meta-analyses concluded that probiotics can be used to prevent antibiotic-
associated diarrhoea in adults and children [53, 54]. Furthermore, there are indications that 
probiotics play an important role in the treatment of Clostridium difficile-associated diarrhoea 
[55, 56], acute rotavirus [57] and other infectious diarrhoea [58]. 
  INTRODUCTION 
   4
Several studies have investigated the efficacy of probiotics in the prevention of traveller’s 
diarrhoea in adults, but methodical drawbacks such as compliance with treatment and 
problems in follow-up limit the validity of these conclusions. Clinical trials have also shown 
that probiotics can prevent allergic symptoms, especially atopic dermatitis [59-62]. Besides, 
probiotics can be used as therapy to reduce severity and frequency of allergic rhinitis [63, 64], 
and to decrease severity and duration of the common cold [65], as well as winter infections 
[66]. Furthermore, clinical studies have shown that probiotics can lead to an improvement in 
inflammatory bowel diseases such as Crohns’ disease [67], ulcerative colitis [68], pouchitis 
[69], Helicobacter pylori infections [70, 71] and reduce cholesterol, as well as triacylglycerol 
plasma concentrations [72]. These numerous effects can hardly be explained by a unifying 
hypothesis based on a single mechanism. It is suggested that probiotic bacteria may exert 
different effects based on specific capabilities and enzymatic activities of different microbes, 
even within one species [73]. For example, benefits may arise from improved resistance to 
pathogens induced through the production of inhibitory substances, blocking of adhesion 
sites, competition for substrates and direct or indirect modulation of specific and non-specific 
immunity [74]. In uncontrolled studies B. bifidum Bb12 (1E10 colony forming units (CFU) 
per day) and L. acidophilus (7E10 CFU/day), each supplement given to 14 volunteers for 
three weeks doubled the numbers of peripheral white blood cells with phagocytic activity 
[75]. Similarly, Lactobacillus rhamnosus subspecies GG (LGG) has been shown to have 
immune modulatory effects. For examples LGG lowered pro-inflammatory cytokines, such as 
tumor necrosis factor alpha (TNF-α) in allergic children [76]. In another study, administration 
of LGG for five weeks to healthy volunteers significantly decreased TNF- α, interleukin-6 
(IL-6) and in part interferon-gamma (IFN-γ) cytokine secretion by peripheral blood cells 
following stimulation, whereas the IL-10 and in part IL-4 cytokine secretion was increased 
[77]. However, long-term intake is necessary to induce beneficial effects, especially since 
probiotic bacteria are rapidly cleared from faeces once daily intake ceased [78]. After four 
days intake they remained in 16% of the individuals and were undetectable eight days after 
cessation of supplementation. This demonstrates one of the key problems of probiotic 
bacteria: the inability of the fed probiotic strain to colonise the colon permanently and thereby 
become an integral part of the microbial community. To overcome these limitations, 
alternative approaches were developed which aimed at a selective stimulation of certain 
beneficial bacteria resident in the gut (like bifidobacteria and lactobacilli) by providing them 
with a specific growth substrate, called a “prebiotic”.   
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1.3 Prebiotics 
 
The term prebiotic was introduced by Gibson and Roberfroid [12] in 1995 who exchanged 
“pro” for “pre”, which means “before” or “for”. They defined prebiotics as “non-digestible 
food ingredients that beneficially affect the host by selectively stimulating the growth and/or 
activity of one or a limited number of bacteria in the colon”. Preferred targets are species 
belonging to the lactobacilli and bifidobacteria genera.  
 
To classify a substrate as “prebiotic” the following criteria must be fulfilled [79]: it must 
- be neither hydrolysed nor absorbed in the upper part of the GIT  
- be selective for one or more potentially beneficial commensal bacteria in the large intestine 
   and encourage their growth and metabolism  
- alter the colonic microenvironment towards a healthier composition  
- induce beneficial luminal or systemic effects that are advantageous to the host. 
 
Non-digestible carbohydrates (NDC), some peptides and proteins, as well as certain lipids 
possess prebiotic properties [5]. In vitro and in vivo data have been published for NDC like 
lactulose, inulin type-fructans, galactooligosaccharides (GOS), fructooligosaccharides (FOS), 
as well as xylo-, isomalto-, gluco- and soya-oligosaccharides [41]. According to the 
Nomenclature Committee of the IUB (NC-IUB) and the IUB-IUPAC Joint Commission on 
Biochemical Nomenclature (JCBN) [80] inulin is a beta (2-1) fructan (chain length 2 to 60 
units; average degree of polymerisation (DPav) = 12); its partial enzymatic hydrolysis product 
is called oligofructose (OF, chain length 2 to 8; DPav = 4, Figure 2). 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Structure of inulin. Inulin is a polysaccharide consisting of beta (2-1) fructosyl 
fructose units (Fn) with normally, but not necessarily, one glucopyranose unit at the reducing 
end (GFn). G, glucose; F, fructose; n, number of fructose moieties [81]. 
n  fructose units
1 glucose unit
GFnFn
n  fructose units
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Inulin and OF are storage carbohydrates in many plants including wheat, onion, banana, 
chicory [79]. Commercial forms of inulin can be extracted from natural sources like chicory 
root or synthesized enzymatically from sucrose [82]. In vitro studies have indicated that inulin 
and OF are preferably fermented by bifidobacteria [83-85] and human in vivo studies have 
confirmed the bifidogenic effect of OF [86-88]. Bifidobacteria possess the cell-bound enzyme 
ß-fructofuranosidase that allows the preferred utilization of fructooligosaccharides [89] and 
offers this genus a competitive advantage over other bacteria in the human gut. The liberated 
fructose moiety is further metabolized in the “bifidus” pathway. Physiologic effects of NDC 
include increase of SCFA production, mineral absorption and vitamin B synthesis [90]. 
 
1.4 The immune system - an overview 
 
Immune responses fall broadly into two categories, innate and adaptive immune responses, 
which work together synergistically [91]. The innate (also termed natural or naive) immune 
system provides the first line of defence against invading organisms without the need of prior 
exposure to their antigens. The cells that mediate innate immunity mainly include phagocytic 
cells (macrophages and neutrophils), inflammatory cells (basophils and mast cells), dendritic 
cells and natural killer cells. The adaptive (also specific or acquired) immune system develops 
during an individual’s life time, is antigen-specific and more efficient upon secondary 
restimulation. It is mediated by lymphocytes (T and B cells) and their products (such as 
cytokines and antibodies) and depends on the presentation of foreign antigens by professional 
antigen presenting cells (APCs) in association with molecules of the major histocompatability 
complex (MHC). Both humoral- and cell-mediated mechanisms are involved in the adaptive 
immune system. Humoral immunity is mediated by antibody secreting B cells, while cellular 
immunity depends on T lymphocytes.  
CD4+ expressing T cells are called T helper cells (Th) and recognize antigens presented in the 
context of MHC class II molecules. CD8+ expressing T cells are called cytotoxic T cells (Tc) 
and recognize antigens presented by MHC class I molecules [92].  
Dendritic cells (DC) play a pivotal role in the initiation of immune responses by priming 
adaptive immunity. Immature DCs migrate through the blood stream and home to various 
peripheral tissues in search of pathogens. Pattern recognition receptors (PRR) such as Toll-
like receptors (TLRs), lectin or intra-cellular nucleotide-oligomerization domain (NOD) 
receptors recognize various pathogen-derived molecules, known as pathogen-associated 
molecular patterns (PAMPs) and lead to an activation of DCs (Figure 3).   
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Upon activation and antigen uptake, DCs down-regulate their endocytotic activity and up-
regulate expression of MHC, as well as adhesion and co-stimulatory molecules, such as 
CD80+ and CD86+, on their surface [93]. Mature DCs then migrate to areas of the draining 
lymph node (into the T cell areas of the secondary lymphoid organs), where they present 
antigen-derived peptides in the context of MHC to the T cell receptor (TCR) of naive 
(CD45RA+) T cells (signal 1, Figure 3). Depending on the nature of the antigen, on the types 
of co-stimulatory molecules, such as CD40+, CD80+, CD86+ (signal 2), and on the 
composition of the T cell polarizing factors, e.g. cytokines, chemokine ligands (signal 3), 
present during the initiation of the T cell response, different T effector subsets develop [94]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. T helper cell stimulation and Th1/Th2 cell polarization requires three dendritic cell 
derived signals. Signal 1 is the “antigen-specific signal”. It is mediated through the binding of 
pathogen-associated molecular patterns (PAMPS) to specialized pattern recognition receptors 
(PRRs) and the triggering of T cell receptor (TCR) by MHC associated peptides. Signal 2 is 
the “co-stimulatory signal”, mainly mediated by the interaction of CD80 and CD86 on DCs 
with CD28 on T cells. Signal 3 is the “polarizing signal” that is mediated by various soluble 
or membrane bound factors, such as cytokines and chemokine ligands, that promote the 
development of Th1 or Th2 cells, respectively (adapted from [94]). 
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Based on their cytokine profiles different functional T helper cell subsets are distinguished 
[94, 95]: CD4+ T helper 1 (Th1) cells produce IFN-γ, and to a lesser extent, IL-2 and IL-12 
that activate macrophages and cytotoxic T cells. They are responsible for cell-mediated 
inflammatory responses against intra-cellular pathogens and viruses and mediate delayed type 
hypersensitivity [96]. CD4+ T helper 2 (Th2) cells synthesize IL-4, IL-5, IL-13 and mediate 
humoral responses by activating B cells, mast cells and eosinophils against extra-cellular 
pathogens (e.g. parasites). Both Th1 and Th2 cells down-regulate each other’s function and 
over-activation of either pattern can cause disease [97].  
Similarly, CD8+ Tc cells can be divided into Tc1 and Tc2 cells [98]. In addition to Th1/Tc1 
and Th2/Tc2 cells a third type of regulatory T cells exists. These include several subsets such 
as natural T reg cells and inducible TR1 and Th3 cells [99, 100]. Regulatrory T cells suppress 
the function of effector cells by releasing the inhibitory cytokine, transforming growth factor-
beta (TGF-ß), and the anti-inflammatory cytokine, IL-10. They play an important role in the 
maintenance of immune tolerance and suppression of immune responses by auto-reactive 
lymphocytes. After priming, clonal expansion and differentiation, the different effector T cell 
subsets acquire new migratory capacities that enable them to re-enter circulation and home to 
the sites of infection.  
 
1.5 Chemokines & chemokine receptors 
 
Homing and migration of leukocytes is a very dynamic process which is orchestrated by the 
regulated expression of different chemokines and chemokine receptors [101]. 
Chemokines (chemotactic cytokines) are small structurally related peptides of 8-10 kilo 
Dalton (~ 100 aminoacids) [102] that function through seven trans-membrane coupled G 
protein receptors, so called chemokine receptors (CKRs) [103]. They have two major roles in 
leukocyte migration: induction of chemotaxis and activation of integrins [104].  
The human chemokine system currently includes more than 50 chemokines and 20 CKRs 
[105]. Chemokines can be divided according to their amino-terminal (NH2-terminal) cysteine 
motifs into four structural subfamilies: C (α), CC (β), CXC (γ) and CX3C (δ) subfamilies 
[106-108] (Table 1). 
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Chemokine receptors 
 
 
Chemokine ligands 
Functional 
classification of 
chemokine 
ligands 
CXC chemokine receptors 
   CXCR3 
   CXCR4 
   CXCR5 
 
IP-10, MIG & I-TAC 
SDF-1/PBSF 
BLC/BCA-1 
 
inflammatory 
homeostatic 
homeostatic 
CC chemokine receptors 
   CCR1 
   CCR2 
   CCR3 
   CCR4 
   CCR5 
   CCR6 
   CCR7  
   CCR8 
   CCR9 
 
MCP-3, MIP-1α & RANTES 
MCP-1, MCP-2, MCP-3 & MCP-4 
MCP-3, MCP-4, Eotaxin 1 & 2, RANTES 
TARC & MDC 
MIP-1α, MIP-1β & RANTES 
LARC 
MIP-3β, ELC & SLC 
I-309 
TECK 
 
inflammatory 
inflammatory 
inflammatory 
both 
inflammatory 
both 
homeostatic 
unknown 
homeostatic 
CX3 chemokine receptor 
   CX3CR1 
 
Fractalkine 
 
inflammatory 
C chemokine receptor 
   XCR1 
 
Lymphotactin 
 
unknown 
Table 1. Summary of some chemokine receptors and their known ligands. Functional 
classification of chemokine ligands into inflammatory and homeostatic chemokines. Some 
chemokines belong to both subfamilies (adapted from [105, 109]). Systematic nomenclature 
for human chemokines can be accessed at http://cytokine.medic.kumamoto-u.ac.jp/. 
IP-10, interferon-γ inducible protein 10 (CXCL10); MIG, monokine-induced by  interferon γ (CXCL9); I-TAC, interferon-inducible 
T cell - α chemoattractant (CXCL11); SDF, stroma cell derived factor1 (CXCL12); PBSF, pre B cell growth stimulating factor; 
BLC, B lymphocyte chemoattractant (CXCL13); BCA-1, B cell attracting chemokine 1 (CXCL13); MCP-1, monocyte 
chemoattractant protein 1 (CCL2); MCP-2 (CCL8); MCP-3 (CCL7); MCP-4 (CCL13); MIP-1〈 macrophage inflammatory protein 
1〈 (CCL3); RANTES, regulated on activation normal T cell expressed and secreted (CCL5); Eotaxin-1 (CCL11); Eotaxin-2 
(CCL24); TARC, thymus- and activation-regulated chemokine (CCL17); MDC, macrophage-derived chemokine (CCL22); LARC, 
liver- and activation-regulated chemokine (CCL20); ELC, Epstein Barr virus–induced receptor ligand chemokine (CCL19); SLC, 
secondary lymphoid tissue chemokine (CCL21); I-309 (CCL1); TECK, thymus-expressedchemokine (CCL25); Fractalkine 
(CX3CL1). 
 
Another classification uses physiologic features (conditions of production and cellular 
distribution of receptors) and divides chemokines into functional subfamilies to distinguish 
between inflammatory (inducible) and homeostatic (constitutive, housekeeping) lymphoid 
chemokines [110, 111]. For example, CCR7 and CCXR4 are known to promote homing of 
naïve T cells and mature DCs to secondary lymphoid organs (lymph nodes, Peyer’s patches). 
In contrast, effector T cells down-regulate CCR7 expression and, depending on the polarizing 
signals, up-regulate typical Th1 CKRs, like CXCR3 and CCR5, or Th2 CKRs, like CCR3, 
CCR4, CCR8 and CRTH2. It must be noted that no single CKR is expressed exclusively 
within one subset [104], and that the combinatorial expression of CKRs fine tunes the 
specificity of leukocyte migration [105]. The appropriate expression of chemokines and their 
receptors facilitates encounters between DC, T and B cells and thereby promotes the 
development of effective adaptive immune responses.  
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1.6 Immune modulatory effects of probiotics & prebiotics  
 
Several recent reviews summarized the available experimental evidence for the immune 
modulatory effects of probiotics [74, 75, 112, 113]. Thus, experimental and human studies 
showed that probiotics affect host resistance to intestinal infections, as well as a number of 
immune cell functions. This includes enhancement of phagocytic activity of peripheral blood 
leukocytes [75] and natural killer cell activity [113], stimulation of both non-specific 
secretory IgA [112, 114], as well as increase of cytokine production in vivo (IFN-γ, IFN-α, IL-
2) and by peripheral blood mononuclear cells ex vivo (IL-1β, TNF-α, IL-6, IL-10, IFN-α, IFN-
γ) [77, 115, 116]. However, the exact underlying immune mechanisms are generally not well 
defined [117]. Similarly, many studies have focused on the effects of prebiotics. Three 
randomized clinical trials (RCT) in infants approved by the European Society for Paediatric 
Gastroenterology Hepatology and Nutrition (ESPGHAN) committee found that 
oligosaccharides softened stool consistency, increased stool frequency [118-120] and even 
lowered faecal pH values, in a dose dependent manner [119]. These studies could also show 
short increases in the total number of bifidobacteria in stools. However, knowledge on the 
long-term health consequences of increased bifidobacterial counts is limited at present and 
data on the efficacy and safety of prebiotics are scare [121]. None of the RCTs assessed 
clinically important functional outcomes (e.g. immune or inflammatory modulation) and long-
term benefits (e.g. GIT infections or allergic diseases). Furthermore, it is unclear whether 
prebiotics directly or indirectly modulate immune responses, for example by altering the 
composition of the intestinal flora or by producing SCFA [122]. Therefore, the ESPGHAN 
committee concluded that no general recommendations on the use of oligosaccharide 
supplementation in infancy as a prophylactic or therapeutic measure can be made [121]. 
Consequently, multidisciplinary approaches are necessary to analyse the interaction of 
probiotics and prebiotics with the immune system.  
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2. AIMS 
 
2.1 Objectives 
 
The objective of the thesis was to investigate the influence of dietary long-term 
supplementation with prebiotics in the last trimenon of pregnancy on the composition of the 
maternal gut and vaginal microbiota and on the neonatal gut colonization in a clinical study. 
In particular, the following hypotheses were tested in this clinical pilot study:  
Long-term supplementation of pregnant women with short-chain galacto-oligosaccharaides 
(GOS) and long-chain fructo-oligosaccharides (FOS) 
1) affects the growth of bifidobacteria and lactobacilli in the maternal gut 
2) stabilizes the vaginal colonization with lactobacilli 
3) influences the gut colonization of the neonate with bifidobacteria and lactobacilli  
4) affects the immune system of the neonate. 
 
2.2 Outcome parameters  
 
Maternal primary outcome variables were the relative numbers of bifidobacteria and 
lactobacilli within the gut microbiota before and after prebiotic supplementation (throughout 
the 3rd trimester of pregnancy). Maternal secondary outcomes were stool frequency, stool 
consistency and vaginal pH values as a proxy for vaginal lactobacilli colonization. In addition, 
acceptance, tolerance and potential side effects that may be associated with the long-term use 
of prebiotics during pregnancy were assessed.  
Primary neonatal outcomes were the analyses of the successive development of neonatal 
microbiota (day 5, day 20 and day 182). Secondary outcomes included a comprehensive 
phenotypical and functional analyses of cord blood (CB) lymphocytes to assess potential 
effects on the immune system.  
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3. STUDY DESIGN, MATERIAL & METHODS 
 
3.1 Study design 
 
To address these hypotheses a randomised double-blind placebo-controlled pilot study was 
designed as depicted in Figure 4. 
 
 
 
 
 
 
 
 
Figure 4. Study design:  * Weekly check of stool frequency and consistency, regurgitation, 
and vaginal pH values. Gestational age (GA). 
 
3.1.1 Study participants  
 
Apparently healthy pregnant women with uncomplicated pregnancies booked for vaginal 
delivery at the Obstetrics’ Hospital or the Department of Obstetrics and Gynaecology 
Großhadern of the Ludwig-Maximilians-University, Munich, Germany, were approached and 
invited to participate in the study. Women aged between 18 - 45 years were only included if 
they planned to deliver in one of the study hospitals and did not intend to donate CB stem 
cells. Allergies were not considered as an exclusion criterion. 
Exclusion criteria were gestational age (GA) above the 24th week at enrolment, acute or 
chronic illnesses, chronic inflammatory bowel diseases (e.g. Crohn’s disease, ulcerative 
colitis), gestational diabetes, intake of anti-inflammatory drugs (glucocorticoides, 
acetylsalicylic acid, non-steroidal anti-inflammatory drugs) or antibiotics and regular 
consumption of pre- or probiotic supplements. Participants were further excluded once they 
discontinued supplementation for longer than two days and for more than two times. Neonates 
with obvious malformation, perinatal asphyxia (5 min APGAR score < 7.0; CB pH < 7.2), or 
with clinical or laboratory signs of a neonatal or maternal infection at delivery were excluded. 
20th GA
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37th GA24th GA Delivery
Cord blood
Maternal blood
Intervention with
prebiotic or placebo supplement
25th GA
* * * * * * * * * * * * * * * *
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The study protocol was approved by the local Ethics Committee of the Bavarian College of 
Physicians (Bayerische Landesärztekammer; # 03041). The CONSORT guidelines [123] 
(recommendations for improving the quality of reports of parallel-group randomized trials) 
were followed. After a careful explanation of the study details, written informed consent was 
obtained from the participants. 
 
3.1.2 Dietary intervention 
 
Pregnant women were randomized to receive daily either a prebiotic supplement containing 
oligosaccharides (GOS and FOS) (prebiotic group) or a placebo supplement containing 
maltodextrin (placebo-group). Participants received the study supplement (provided by 
NUMICO Research, Friedrichsdorf, Germany), free of charge, delivered to their homes. The 
complete amount of supplement necessary for at least 15 weeks of supplementation was 
provided in seven packages each containing 50 sachets. Each sachet contained 6 gram (g) of 
supplement and was blinded with a special code: “N” or “O”. Detailed consumption 
instructions were given on the label of each sachet.  
Six g of the water-soluble powder product contained either 3 g of GOS/FOS (Raftiline HP, 
provided by NUMICO Research, Friedrichsdorf, Germany) in a ratio of 9:1 (prebiotic 
supplement) or 6 g of maltodextrin (placebo supplement) (Table 2).  
 Prebiotic (%) Placebo (%) 
Galactose 0.76 - 
Glucose 14.39 - 
Lactose  15.15 - 
FOS (Fructooligosaccharides) 4.91 - 
GOS (Galactooligosaccharides) 45.45 - 
Maltodextrin  19.34 100 
Table 2. Composition of the prebiotic and the placebo supplement (per 100 mL). 
 
Maltodextrin was chosen as the placebo control because, in contrast to oligosaccharides, it is 
completely digested in the upper intestinal tract and does not interfere with the metabolic 
activity of the colonic flora. The sensory and other characteristics of the prebiotic and placebo 
preparation were virtually indistinguishable.  
Women were instructed to consume three sachets per day by mixing the supplement with 200 
mL of water or milk starting from the 25th week of gestation until delivery. They were further 
asked to maintain their habitual diet throughout the intervention period. To provide some 
dietary variation, the participants were allowed to use non-probiotic yogurt to mix the 
supplement.  
 
 STUDY DESIGN, MATERIAL & METHODS 
   14
3.1.3 Randomization & allocation 
 
The sample size was based on the described concentration of bifidobacteria in faecal samples. 
With a sample size of at least 15 participants per group, it is possible to detect a mean 
difference of 30% in bifidobacteria, with a probability of 80% and a (2-sided) significance 
level of 0.05 [30]. A computerized randomization list using a 4 block design (total sample 
size: 30; number of treatments: 2) was used to implement the random allocation sequence. 
The randomization was generated by NUMICO Research, Germany. The volunteers were 
allocated by sequential numbers at study entry to one of the two supplementation groups, and 
the allocated number was subsequently kept throughout the study. Participants who failed to 
complete the study (e.g. in case of revocation of written consent), or dropped out (e.g. because 
of medical problems or discontinuation of supplementation before study end) were replaced 
according to the randomization list. We assumed that the study withdrawal rate would be at 
least 25%. Based on this, we estimated that at least 19 participants must be enrolled into each 
group. In the case of  > 30% missing data the concerned subject was excluded from the study 
and subsequent statistical data evaluation. All study personnel and participants were blinded 
to treatment assignments for the duration of the study. The code was revealed to the 
researchers once data collection and laboratory analyses were complete.  
 
3.1.4 Questionnaires  
 
At study entry, the atopic status of the family (mother, father and siblings) was assessed in a 
standardized personal face-to-face interview that included information on allergic diseases 
(allergic asthma (diagnosed by a doctor), hay fever, seasonal allergies, atopic eczema, 
urticaria, food allergies) and smoking habits (appendix: 9.6.1 Questionnaire 1). Self-assessed 
questionnaires were used to collect weekly data on gastrointestinal bowel behaviour (stool 
frequency, stool consistency, incidence of regurgitation) and vaginal pH-values (CarePlan 
VpH) throughout the study (appendix: 9.6.2 Questionnaire 2 and 9.6.3 Questionnaire 3). 
Participants were contacted at three week intervals via telephone to promote adherence to the 
protocol and to assess occurrence of side effects and complaints. The phone numbers of the 
study coordinators were available to the participants at all times to ask questions and/or to 
report perceived problems or concerns. At delivery, birth details were collected from the 
hospitals’ maternal birth records, i.e. information about gravity, parity, gravity risks, maternal 
weight and height, pregnancy complications, mode of delivery and delivery complications 
(proteinuria, blood pressure, occurrence of eclampsia, and estimated blood loss). Furthermore, 
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foetal anthropometric measures such as birth weight and length, head circumference and 
APGAR scores were assessed. At study end, compliance, overall tolerance and acceptance, as 
well as occurrence, intensity and duration of complaints and side effects, such as abdominal 
pain, distension and flatulence were assessed (appendix: 9.6.4 Questionnaire 4). Protocol 
adherence was checked by counting the number of returned sachets at the end of the study. 
When the infants were six months of age (day 182) a standardized follow-up telephone 
interview was conducted with the participants (appendix: 9.6.5 Questionnaire 5). The follow-
up questionnaire was adapted from the GINI (German Infant Nutritional Intervention 
Programm) study [32, 124] and included a series of questions regarding feeding habits, 
medication, infections and atopic dermatitis of the neonate. 
 
3.1.5 Study samples 
 
Stool sampling:  
Two stool samples were taken from the mother before supplementation begin (before the 25th 
week of gestation) and an additional two samples shortly before expected delivery (Figure 4). 
Furthermore, two stool samples from the neonate were taken after 5 and 20 days post partum 
and at the age of six months (~ day 182). Women were asked to freeze the samples at - 20 °C 
within 20 min after collection and to inform the study coordinators. Frozen samples were 
transported with cool packs by taxi and stored at - 20 °C until analyses. 
 
Blood sampling: 
Placental venous CB was collected to assess the neonatal immune function (see methods 
below). The CB samples were collected into 7.5 mL ethylene diamine tetra acetate (EDTA) 
and 7.5 mL lithium heparin (LH) blood collection tubes from the placental vein immediately 
after delivery. Maternal peripheral blood was collected into 7.5 mL EDTA-tubes after 
delivery by venous puncture (Figure 4).  
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3.2 Materials 
 
3.2.1 Instruments & software 
 
Instrument [Software] Company 
Personal Computer (PC) with 
[Windows XP office package] 
[SPSS V12] 
[Reference Manager] 
IBM, Heidelberg, Germany 
BD FACSCanto  with 
[BD FACSDiva Software] 
BD Biosciences, Heidelberg, 
Germany 
Bio-Plex Suspension Array Reader with 
[Bio-Plex-Manager SoftwareTM V 3.0] 
BioRad, Laboratories Hercules, 
Carlif. USA 
Blood counter: XT-1800i Haematology Analyser Sysmex America, Inc. Mundelein, 
USA 
Rotanta centrifuge 460 R Hettich, Tuttlingen, Germany 
Eppendorf table centrifuge 5415C Eppendorf, Hamburg, Germany 
Research pipettes (0-2 µL, 2-20 µL, 10-100 µL, 100-100 µL) Eppendorf, Hamburg, Germany 
Eppendorf Easypet 4421 (pipetboy) Eppendorf, Hamburg, Germany 
Flow TitertekMultichannel Pipette (50-300 µL)  Flow Titertek Labsystems, 
Finnland 
Vortex-Genie 2 Scientific Industries, Bohemia, NY, 
USA 
96-well Vacuum pump BioRad, Laboratries GmbH, 
Munich, Germany 
Rotamax 120  Heidolph Instruments GmbH & Co 
KG, Schwabach, Germany 
Carbon dioxide (CO2) Incubator BB6060 Hereaus Instruments, Thermo 
Electron Corporation, 
Langenselbold, Germany 
LaminAir  HBB 2472 Hereaus Instruments, Thermo 
Electron Corporation, 
Langenselbold, Germany 
+ 4 °C Fridge Gerlingen-Schillerhöhe, Germany 
- 20 °C Freezer Siemens, Munich, Germany 
- 80 °C Freezer  Kendro, Thermo Electron 
Corporation, Langenselbold, 
Germany  
Table 3. Instruments and software. 
 
3.2.2 Consumables 
 
Consumables Company 
S-Monovette 7.5 mL K3E (EDTA-tubes) Sarstedt, Nümbrecht, Germany 
S-Monovette 7.5 mL LH (Lithium-Heparin tubes) Sarstedt, Nümbrecht, Germany 
Sarstedt Serological pipettes (5 mL, 10 mL, 25 mL) Sarstedt, Nümbrecht, Germany 
epT.I.P.S. Standard (2-200 µL, 500-1250 µL) Eppendorf, Hamburg, Germany 
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Eppendorf cups (1.5 mL, 2 mL) Eppendorf, Hamburg, Germany 
Cellstar PP Test Tubes (15 mL, 50 mL) Greiner bio one, Frickenhausen, 
Germany 
BD Falcon, 5 mL Polystyrene Round Bottom Tube  BD Biosciences Discovery, 
Heidelberg, Germany 
Tissue Culture Plate, 24-well, flat bottom BD Labware, Heidelberg, Germany
Spatula containers (polyethylene stool sample tubes) Engelbrecht, Edermünde, Germany 
Cool pads Mack Ges.m.b.H, Altenmarkt 
Austria 
CarePlan VpH test gloves  Inverness medical Unipath 
Diagnostics, Cologne, Germany 
Table 4. Consumables. 
 
3.2.3 Reagents  
 
Reagents  Company 
Aqua bidestileta Gibco, Invitrogen Life 
Technologies; Karlsruhe, Germany 
RPMI 1640 Gibco, Invitrogen Life 
Technologies; Karlsruhe, Germany 
Trizol LS Reagent Invitrogen Life Technologies, 
Karlsruhe, Germany 
Phosphat-Buffered-Saline (PBS) pH 7.2 - CaCl2 - 
MgCl2 
Gibco, Invitrogen Life 
Technologies; Karlsruhe, Germany 
BD FACSFlow BD Biosciences, Heidelberg, 
Germany 
BD FACSClean BD Biosciences, Heidelberg, 
Germany 
BD FACS Lysing Solution (10x) BD Biosciences, Heidelberg, 
Germany 
Staphylococcal enterotoxin B (SEB) Sigma Chemical Co., Deisenhofen, 
Germany 
Beta-lactoglobulin (BLG) Sigma Chemical Co., Poole, UK 
Concavalin A (Con A) Sigma Chemical Co., Poole, UK 
Ovalbumin (OVA) Sigma Chemical Co., Poole, UK 
Lipopolysaccharid (LPS) Sigma Chemical Co., Poole, UK 
Dermatophagoides pteronysinus 1 (Der p1) 
affinity purified 
Indoor Biotechnologies, Cardiff, 
UK 
Bio-Plex Suspension Array System 
   8plex: TNF-α, IFN-γ, IL-1β, IL-2, IL-4, IL-10, GM-  
              CSF, G-CSF 
   4plex: IL-6, IL-8, IL-10, MCP-1, MIP-1ß IL-7, IL-5,   
              IL-12, IL-13, IL-15 
BioRad, Laboratories, Hercules, 
Carlifornia, USA 
Table 5. Reagents. 
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3.2.4 Antibodies 
 
For flow cytometric staining anti-human monoclonal antibodies labelled with fluorescein 
isothiocyante (FITC), phycoerythrin (PE), phycoerythrin-cyanin 5 (PC5), or allophycocyanin 
(APC) were used in the following dilutions (Table 6). 
Antibodies Fluorochrome Dilution Isotype Company 
CD45RA PC5 1 : 4 MouseIgG2b,k BD Biosciences 
CD45RO APC 1 : 4 IgG2ak BD Biosciences 
CD4 APC 1 : 2 Mouse IgG1,k BD Biosciences 
CD8 APC 1 : 2 MouseIgG1,k BD Biosciences 
CD14 FITC 1 : 2 Mouse IgG2a,k BD Biosciences 
CD69 FITC pure Mouse IgG1,k BD Biosciences 
CD8 FITC 1 : 2 RPA-T8 BD Biosciences 
CD25 PE 1 : 2 MouseIgG1,k BD Biosciences 
TLR2 PE 1 : 2 Mouse IgG2a,k eBiosciences 
TLR4 PE 1 : 2 MouseIgG2a,k eBiosciences 
CRTH2 PE 1 : 2 ratIgG2a Miltenyi Biotec 
CCR1 PE 1 : 2 Mouse IgG2B R&D Systems GmbH 
CCR2 PE 1 : 2 Mouse IgG2B R&D Systems GmbH 
CCR4 PE 1 : 2 IgG1,k BD Biosciences 
CCR5 PE 1 : 2 Mouse IgG2a,k BD Biosciences 
CCR6 PE 1 : 2 Mouse IgG2B R&D Systems GmbH 
CCR7 PE 1 : 4 Mouse IgG2A R&D Systems GmbH 
CCR8 PE pure Rat IgG2b R&D Systems GmbH 
CCR9 PE pure Mouse IgG2A R&D Systems GmbH 
CXCR3 PE 1 : 4 MouseIgG1,k R&D Systems GmbH 
CXCR4 PE 1 : 2 IgG2A R&D Systems GmbH 
CXCR5 PE 1 : 2 Mouse IgG2B R&D Systems GmbH 
IgG1 / IgG1 FITC/PE pure - BeckmannCoulter 
IgG1 / IgG2a FITC/PE pure - BeckmannCoulter 
Table 6. Antibodies used for flow cytometric staining (BD Biosciences, Heidelberg, Germany; 
eBioscience, San Diego, USA; Miltenyi Biotec, Bergisch-Gladbach, Germany; R&D Systems GmbH, 
Wiesbaden-Nordenstadt, Germany; Beckman Coulter, Krefeld, Germany). 
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3.3 Methods 
 
3.3.1 Microbial stool sample analyses 
 
Collected samples were sent on dry ice to the Department of Biomedical Research, 
(NUMICO Research, Wageningen, Netherlands) where DNA isolations, DAPI, FISH and 
qPCR analyses were preformed (by Monique Haarman and Dr. Jan Knol). Stool samples were 
thawed and the pH was measured directly with a Handylab pH meter (Schott Glas, Mainz, 
Germany) equipped with an Inlab 423 pH electrode (Mettler-Toledo, Columbo, U.S.A.). 
Samples were diluted 10-fold in milliQ and homogenized with a stomacher (IUL Instrument, 
Barcelona, Spain). The suspensions used for DNA extractions were subsequently frozen at  
- 20 °C until further analyses 
For the fluorescent in-situ hybridization (FISH) analysis 1 mL of the homogenized faecal 
suspension was fixed in 3 mL freshly prepared 4% (w/v) paraformaldehyde in phosphate 
buffered saline (PBS) and incubated overnight at + 4 oC. The total number of bacteria was 
determined by 4´,6-diamino-2-phenylindole (DAPI) staining and the percentage of 
bifidobacteria and lactobacilli were determined by fluorescence in situ hybridisation (FISH), 
as described [30, 125] with some slight modifications.  
Prior to the DNA isolation, the homogenized faecal samples were thawed at room 
temperature. The DNA isolations were carried out according to manufacturer’s instructions 
(NucliSense Isolation Extraction Kit; BioMerieux, Boxtel, The Netherlands).  
For the relative quantification of the genera Bifidobacterium and Lactobacillus and the 
different bifidobacterial and lactobacilli species, duplex 5’ nuclease (qPCR) assays were used 
[126, 127]. Briefly, with different primer and probe combinations (appendix: 9.4 Primers 
and Probes used for the duplex 5’ nuclease assays), a temperature profile consisting of two 
minutes (min) at + 50 °C, 10 min at + 95 °C, followed by 45 cycles of 15 seconds (sec) at + 
95 °C and 60 °C for one min was run on an ABI Prism 7900HT (Applied Biosystems, 
Nieuwerkerk a/d IJssel, The Netherlands). Thereafter, the percentages were determined 
according to Liu et al. [128]. The minimum detection threshold of FISH was 10E6 cells per g 
wet weight of faeces and the detection limit of the qPCR analyses was 0.00001%.  
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3.3.2 Flow cytometry 
 
CB anti-coagulated with EDTA was processed and analysed within 4 h after blood collection. 
Optimised amounts of fluorochrome-conjugated antibodies were added to 50 µL whole CB 
(Table 7). For phenotypical analyses of T lymphocytes 4-colour cytometry with PE-
conjugated monoclonal antibodies against different chemokine receptors (CKR), was used in 
combination with monoclonal antibodies against the naive lymphocyte marker CD45RA- 
(labelled in PC-5), the T helper cell marker CD4+ (labelled in APC) and the T cytotoxic cell 
marker CD8+ (labelled in FITC) (tubes 3 - 14). In addition, activation makers (CD25 and 
CD69) were assessed on CD4+ and CD8+ cells (tubes 15 and 16) and Toll-like receptors 
(TLR2 and TLR4) were analysed on CD14+ expressing monocytes (tubes 1 and 2). 
Appropriate isotype controls of immune globulin 1 (IgG1) and 2a (IgG2a) were always 
included (tubes 17 and 18). After addition of the respective antibodies to each tube, samples 
were mixed for 30 sec and incubated for 20 min at + 4 °C in the dark. 
Tube 
number 
PC5 
Phycoerythrin-
cyanin 5 
APC 
Allophycocyanin 
FITC  
Fluorescein 
isothiocyante 
PE  
Phycoerythrin 
1 CD45RA CD4 CD14 TLR2 
2 CD45RA CD4 CD14 TLR4 
3 CD45RA CD4 CD8 CCR1 
4 CD45RA CD4 CD8 CCR2 
5 CD45RA CD4 CD8 CCR4 
6 CD45RA CD4 CD8 CCR5 
7 CD45RA CD4 CD8 CCR6 
8 CD45RA CD4 CD8 CCR7 
9 CD45RA CD4 CD8 CCR8 
10 CD45RA CD4 CD8 CCR9 
11 CD45RA CD4 CD8 CXCR3 
12 CD45RA CD4 CD8 CXCR4 
13 CD45RA CD4 CD8 CXCR5 
14 CD45RA CD4 CD8 CRTH2 
15 CD45RA CD4 CD69 CD25 
16 CD45RA CD8 CD69 CD25 
17 CD45RA CD45RO IgG1 IgG1 
18 CD45RA CD45RO IgG1 IgG2a 
Table 7. Antibody combinations used for CB staining. 
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Stained cells were washed twice by centrifugation (3 min, 3000 rpm) with 1 mL PBS to 
remove unbound antibodies. Contaminating erythrocytes were lysed using 0.3 mL BD 
FACS 1x lysing solution. Samples were analysed immediately afterwards. Cells were 
acquired on a BD FACS-Canto flow cytometer (equipped with a 488-nm blue laser and a 635-
nm red diode laser for multicolour measurements) and analysed using BD FACS-Diva 
Software. Initial gating with forward scatter (FSC) on the x-axis and side scatter (SSC) on the 
y-axis served to exclude debris and dead cells (threshold = 50). 
An acquisition gate was set according to forward and side light scattering cell properties to 
collect only the lymphoid population (Figure 5a). A minimum of 10,000 lymphocytes was 
acquired (tubes 3 - 14). Same antibody batches were used to reduce intra-assay variability. In 
addition, laser and photomultiplier parameters were kept constant for all experiments.  
CB contains nucleated red blood cells (NRBCs), which do not get lysed by lysis solution and 
which overlap with FSC-SSC characteristic of the lymphocytes. Therefore, a gate was set on 
CD4+ expressing cells in the CD4+-SSC plot (P1 in red) to exclude NRBCs from analyses in 
all samples (Figure 5b). After defining a cut-off value according to the isotype controls (tubes 
17 and 18), the frequency of CD45RA+ (quadrant 2, Q2), CKR+ (Q2-1) and CKR+CD45RA+ 
(Q2-2) expressing cells were analysed within the CD4+ population (Figure 5c, 5d, 5e).  
A second gate (P2 in green) was set on CD4+CD4RA+ cells (Figure 5f) to determine the 
frequency of CKR+ expressing cells within this subset (Q2-3 = Q2-4, Figure 5g, 5h). The 
same analyses procedure was performed for determining the frequency of CKR+ expressing 
CD8+ and CD8+CD45RA+ cells.  
Since CXCR4 is a heterogeneously expressed receptor on lymphocytes (tube 12), a gate was 
set on CXCR4+ expressing cells in the CXCR4+-SSC plot and the mean fluorescence intensity 
(MFI) was determined on the different CD4+ and CD8+ T cell subsets. The gating strategy for 
CXCR4+ is comparable to the gating strategy for TLR+ expression on CD14+ monocytes. 
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Population hierarchy and statistics. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Gating strategy for determining the frequency of CKR+ expressing CD4+ cells. An 
acquisition gate was set on the lymphocytes according to the FSC and SSC (a). A gate was set 
on CD4+ cells (P1 in red) in a CD4+-SSC plot (b) and the frequencies of CD45RA+ (c) and 
CKR+ (d) and CKR+CD45RA+ (e) expressing CD4+ cells was analysed within this gate. A 
second gate (P2 in green) was set on the CD4+CD45RA+ cells (f) to analyse the frequency of 
CKR+ expressing cells (g, h) within the CD4+CD45RA+ population. Population hierarchy and 
statistics (number (#) of events and their percentages (%) in each gate (P) and quadrant (Q)) 
are shown in the table besides. 
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To determine the frequency of CD4+CD25high expressing T cells a gate (P1 in red) was set on 
CD4+ expressing cells in the CD4+-SSC plot (Figure 6a). To discriminate between CD25high 
T cells (which presumably represent T regulatory cells) from CD25intermediate activated effector 
T cells, CD25 expression on CD8+ cells was used as internal control. Therefore, a backward 
gating strategy was applied to set a second gate (P2 in green) on lymphocytes (Figure 6b) and 
CD25 expression on CD4+ and CD8+ cells was compared (Figure 6c). CD8+ (CD4-) cells 
express almost exclusively intermediate levels of CD25, whereas CD4+ T cells express CD25 
with high (CD25high) or intermediate (CD25intermediate) intensities [129]. Only CD4+ cells 
expressing CD25 with higher intensities than the CD8+ cells (above blue cut off line) were 
included in the analysis. The frequency of CD25high (Q2, Figure 6d) and of 
CD45RA+CD25high expressing cells (Q2-1, Figure 6e) were determined within the CD4+ 
population. A second gate (P3 in blue) was set on the CD4+CD25high subset and the frequency 
of CD45RA+ cells (Q2-2, Figure 6f) within this subset was determined (tube 15). Gating 
strategy was confirmed by analyses of CD8+CD25+CD45RA+ labelled cells (tube 16). 
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Figure 6. Gating strategy for determining the frequency of CD4+CD25high T regulatory cells. 
A gate (P1 in red) was set on CD4+ cells in the CD4+-SSC plot (a). For discrimination 
between CD25high, CD25intermediate and CD25low cells a cut-off line (blue) was set between the 
CD25high, CD25intermediate cells by comparing the CD25 expression levels on CD4+ and CD8+ 
cells (c). For this a gate (P2 in green) was set on the lymphocyte population (b). In a first 
analyses the frequency of CD25high (d) and CD45RA+CD25high (e) expressing cells within the 
CD4+ population were determined. A second gate (P3 in blue) was set on CD4+CD25high 
population (f) and the frequency of CD45RA+ expressing cells within this subset was 
determined (g). Population hierarchy and statistics (number (#) of events and their 
percentages (%) in each gate (P) and quadrant (Q)) are shown in the table besides. 
 
 
 
 
 
e
f
a
d
b
g
CD25high
CD25intermediate
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c
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To determine the expression of TLRs on monocytes, an acquisition gate (P1 in red) was set on 
the CD14+ expressing cells in the CD14+-SSC plot (Figure 7). The MFI of TLR2 and TLR4 
was determined within this gate (tubes 1 and 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
    Population hierarchy and statistics.  
 
 
 
 
 
 
 
Figure 7. Gating strategy for TLR+ expression on CD14+ monocytes. A gate was set on the 
CD14+ cells in the CD14+-SSC plot and MFI of TLR was determined within this gate. 
Population hierarchy and statistics (number (#) of events and their percentages (%) in each 
gate (P) and quadrant (Q)) are shown in the table below. 
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3.3.3 Simulation assay 
 
Lithium heparinized CB samples were diluted 1 in 5 with RPMI-1640. Adapting a technique 
by E. Miles et al. [130] aliquots of 1 mL diluted CB were stimulated with the mitogen 
concavalin A (Con A 50 µg/mL), the food allergens beta-lactoglobulin (100 µg/mL BLG), 
ovalbumin (100 µg/mL OVA), the bacterial stimuli lipopolyssaccharid (0.1 µg/mL LPS), 
staphylococcal enterotoxin B (0.1 µg/mL SEB), the inhalative house dust mite allergen 
Dermatophagoides pteronyssinus (10 µg/mL Der p1) or medium alone in a 24-well culture 
plate. Stimuli were pre-aliquoted for each experiment to reduce intra-assay variability. Cells 
were incubated at + 37 °C in a 5% CO2-atmosphere for 24 h and 48 h.  Supernatants were 
collected after centrifugation (3000 rpm for 5 min) and aliquots of 200 µL were stored for 
cytokine analyses at - 80 °C.  
 
3.3.4 Multiplex cytokine array  
 
The cytokine content of the stimulated CB supernatants was measured with a human 
multiplex, particle-based, flow cytometric assay. In short, premixed dyed 5.5 µm polystyrene 
beads (50 µL per well) coated with target capture antibodies specific for different cytokines 
(5000 beads per cytokine) were incubated with premixed cytokine standards or sample (50 
µL) supernatants in 96-well filter plates. Plates were shaken for 30 sec at high speed (1000 
rpm) and then incubated at room temperature for 30 min at low speed (300 rpm). Following 
incubation and washing, the bound cytokines were detected with premixed biotinylated 
detection antibodies (50 µL per well). After incubation and washing, streptavidin-
phycoertythrin (25 µL streptavidin-PE per well) was added to the wells and the plates were 
shaken again for 10 min at room temperature. Finally, beads were washed, resuspended in 125 
µL of Bio-Plex cytokine assay buffer and read by the Bio-Plex Suspension Array Reader 
(flow cytometric microtiter plate reader system). Data were analysed using Bio-Plex-Manager 
SoftwareTM (V 3.0) with 5 PL (5 parameter logistic regression algorithms) curve fits. The 
unknown concentrations were deduced from the cytokine standard curves and values above 
detection limits were excluded from further analyses.  
Detection limits for the cytokines were 2 - 32000 pg/mL. TNF-α, IFN-γ, IL-1β, IL-2, IL-4, 
IL-5, IL-7, IL-10, IL-12, IL-13, IL-15, GM-CSF, G-CSF concentrations were directly 
measured without further dilution of the supernatants. Supernatants were diluted 1:10 in 
RPMI to determine the concentrations of IL-6, IL-8, MCP-1 and MIP-1ß. The differences in 
cytokine expression, as compared to the negative control, were determined and concentrations 
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were normalized to the number of lymphocytes (for IL-2) and leukocytes (for all other 
cytokines) obtained from the whole blood counts (pg/mL/10E3 cells). 
 
3.3.5 Statistical analyses 
 
Continuous data were tested by Kolmogorov-Smirnov test to determine if they were normally 
distributed. Normally distributed data were analyzed by the two-tailed t-test. For non-
parametric data a two-tailed Mann-Whitney U-test (MWU) test was used. Descriptive results 
are expressed as median with ranges. Intra-group comparisons (compared to baseline) were 
performed using paired Wilcoxon test. For ordinal and nominal (categorical) data, the percent 
frequencies were calculated and the differences were determined using Pearson Chi square 
(χ2) test. Differences within one group (intra-group comparisons) were calculated by the 
McNemar test. For repeated measurements, Friedmans test was used to assess differences 
within one group over time. Bacterial data were analysed as (a) continuous data and (b) 
dichotomous data (i.e. detected or not detected). Correlations (between mother and infant 
faecal bifidobacteria and lactobacilli colonization) were assessed using Spearman’s rank 
correlation test. The bacterial diversity index (DI) was calculated using the following equation 
DI = (A/B) x 100, with “A” representing the number of species detected in a sample and “B” 
representing the total number of analyzed species (for bifidobacteria n=9 and for lactobacilli 
n=8). The bacterial similarity index (SI) between mother and infant pairs was determined 
using the following equation: SI = (C/D) x 100, with “C” representing the number of mother-
infant species that matched, i.e. that were detectable in both mother and infant (species that 
were detected only in the mother or only in the infant were considered as not matching) and 
“D” representing the number of all species which were either positive in the mother and/or the 
infant. A probability level of below 0.05% was considered to be statistically significant.  
To correct for multiple testing, the significance value was set to 0.003 (17 parameters tested 
by FACS; 17 bacterial species analysed by FISH and qPCR) or 0.004 (12 cytokines measured 
by Bioplex). Due to the exploratory nature of this study, we did not wish to exclude any 
important relationships by using stringent correction factors for multiple analyses. However, 
we recognize the potential for type 1 error, and data have been interpreted conservatively in 
this respect. Accordingly, our discussion has focussed on differences that are most likely to be 
of biological significance (namely differences of p<0.001).  
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4. RESULTS 
 
4.1 Recruitment of study participants and sample collection 
 
A total of 200 pregnant women between the 20th and 24th week of gestation were assessed for 
eligibility (Figure 8). Of these, 75 women were not interested in participating in the study. 
From the remaining 125 women, 77 women were excluded because they did not fulfil the 
inclusion criteria: 37 planned to deliver at other hospitals, 22 planned to donate stem cells and 
18 needed medications.  
Thus, 48 women consented to participate and were randomly assigned to one of the two 
supplementation groups. From these, seven women dropped out because of personal or 
medical reasons (movement to another city, delivery in another hospital, complications during 
pregnancy, gestational diabetes, anti-inflammatory medication). Five women were excluded 
because of non-compliance with the study procedures (interruption of supplementation for 
longer than two days and for more than two times), which was unrelated to the supplement 
assignment. Additionally, three women did not complete the study because they did not 
tolerate the supplementation: one woman from the prebiotic group suffered from constipation 
and bloating and two women from the placebo group stopped supplementation because they 
suffered from diarrhoea or reflux. Thus, 33 women completed the study (17 participants in the 
prebiotic group and 16 participants in the placebo group (drop out rate 31%). All women 
started supplementation at the 25th week of gestation up to delivery. Recruitment started in 
March 2004 and continued until July 2005. Follow-up ended in January 2006.  
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Figure 8. Flowchart of participant recruitment, sample collection and follow-up.   
* one twin pregnancy in each group. 
Explanation for the missing stool samples: 
Maternal stool samples at the 37th GA: two mothers from the placebo group forgot to immediately freeze the 
stool samples after collection. Neonatal stool samples from day 5: one mother from the prebiotic and one from 
the placebo group were unable to collect a sample from the diapers of their babies. Neonatal stool samples from 
day 20: one mother from the placebo group forgot to immediately freeze the neonatal stool sample after 
collection and one sample from the placebo group did not contain enough material for analysis. Neonatal stool 
samples from day 182: one neonatal sample form the prebiotic group and two from the placebo group were not 
obtained due to loss of contact to participating women. 
Explanation for the missing blood samples: 
Maternal blood samples at delivery (blood count and serum): three mothers from the placebo group delivered at 
other hospitals. Cord blood samples at delivery (blood count, serum, flow cytometry, stimulation assay): three 
mothers from the placebo group delivered at other hospitals. Two CB tubes from the prebiotic group did not 
contain enough material for performing the flow cytometric analyses and the stimulation assay. One additional 
CB tube from the placebo group did not contain enough material for performing the stimulation assay. 
Explanation for the missing follow-up interviews:  
Contact was lost to one woman from the prebiotic and two women from the placebo group. 
Assessed for eligibility 
n=200
Excluded (n=152)
- Refused to participate (n=75)
- Did not meet inclusion criteria (n=77)
1. Maternal stool samples
- 24th week of gestation (n=17)
- 37th week of gestation (n=17)
2. Maternal blood
- blood count (n=17)
- serum (n=17)
1. Maternal stool samples
- 24th week of gestation (n=16)
- 37th week of gestation (n=14)
2. Maternal blood
- blood count (n=13)
- serum (n=13)
Randomized
n=48
Allocated to prebiotic intervention: n=24
- Did not receive allocated intervention: n=7 
- delivery at another hospital (n=1)
- relocation (n=1)
- gestational diabetes (n=1)
- poor compliance (n=3) 
- constipation, bloating  (n=1)
- Received allocated intervention: n=17
Number of neonates: n=18 *
1. Neonatal stool samples
- day 5 (n=17)
- day 20 (n=18)
2. Cord blood samples
- blood count (n=18)
- flow cytometry (n=16)
- stimulation assay (n=16)
Number of neonates: n=17 *
1. Neonatal stool samples 
- day 5 (n=16)
- day 20  (n=15)
2. Cord blood samples 
- blood count (n=14)
- flow cytometry (n=14)
- stimulation assay (n=13)
Allocated to placebo intervention: n=24
- Did not receive allocated intervention: n=8
- delivery at another hospital (n=1)
- complications during pregnancy (n=1)
- gestational diabetes (n=1)
- medication (n=1) 
- poor compliance (n=2)
- diarrhoea (n=1) 
- reflux (n=1)
- Received allocated intervention: n=16
6 months (~ day 182)
- Telephone interview (n=16)
- Neonatal stool samples (n=17) 
6 months (~ day 182)
- Telephone interview (n=14)
- Neonatal stool samples (n=15)
collected & 
analyzed samples
allocation
follow-up
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4.2 Analyses of questionnaires 
 
4.2.1 Baseline characteristics  
 
The baseline characteristics of the study population are summarized in Table 8. At study 
entry, participants did not differ in age and smoking habits. Paternal allergies and allergies in 
siblings showed no significant differences between both groups (data not shown). 
Mother 
Prebiotic 
(n=17) 
Placebo  
(n=16) 
P 
Age at study entry1 
    median  
    (range) 
 
33 
(23 - 48) 
 
35 
(22 - 43) 
0.096 
Allergies 
    allergic asthma  
    hay fever 
    seasonal allergies 
    atopic eczema 
    urticaria 
    food allergies 
 
4 (23.5) 
7 (41.2) 
6 (35.3) 
6 (35.3) 
4 (23.5) 
6 (35.3) 
 
3 (18.7) 
9 (56.3) 
8 (50.0) 
5 (31.3) 
2 (12.5) 
4 (25.0) 
 
0.737 
0.387 
0.393 
0.805 
0.412 
0.520 
Smoking 
    yes 
    no 
 
1 (5.9) 
16 (94.1) 
 
1 (6.3) 
15 (93.7) 
0.965 
Table 8. Baseline characteristics of the study group. 1Results are expressed as median (range) for 
continuous variables and numbers of subjects (%) for dichotomous variables. Differences between both groups 
were calculated with MWU test for continuous data or χ2 test for dichotomous data.  
 
4.2.2 Study population at delivery 
 
Apart from two women with twin pregnancy (one gemini in the prebiotic-group and one in the 
placebo group) all women had a singleton pregnancy. All participants, except three women 
from the placebo group, delivered at one of the two study hospitals. Infants were born 
between the 36th - 41st week of gestation. Four participants from the prebiotic group (one with 
a twin pregnancy) and one participant from the placebo group delivered by caesarean section. 
No significant differences concerning body mass index (BMI), parity risks, maternal blood 
loss, mode of anaesthesia, and maternal blood count parameters (leukocytes, %-lymphocytes, 
haemoglobin) were observed between the groups (data not shown). The supplement was 
equally well accepted by all participants who completed the study. The median duration of 
supplementation was 3.4 - 3.8 months. All 33 participants reported full compliance with the 
intervention regime (none interrupted supplementation for longer than two days and for more 
than two times). Overall tolerance of both supplements was good. Complaints about reflux, 
bloating and abdominal pain were reported equally in both groups (Table 9).  
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No major side effects of the treatment were observed. All women stated that dissolving the 
powder supplement in fluids three times daily was too time consuming and claimed that they 
would have preferred taking capsules instead. Birth data were obtained from the all except 
three neonates whose mothers did not deliver at one of the two study hospitals. After 
supplementation, no significant differences were observed between both groups concerning 
APGAR, umbilical pH, as well as birth weight and length. Three infants from the prebiotic 
group and two from the placebo group were treated with antibiotics in the first three weeks of 
life for four to seven days. Antibiotic treatment was necessary because of amnion infection 
(n=4). 
 
Mother 
Prebiotic 
(n=17) 
Placebo  
(n=16) 
P 
Pregnancy1 
    singleton 
    gemini 
 
16 (94.1) 
1 (5.9) 
 
15 (93.8) 
1 (6.3) 
0.965 
Gestational age 
     median  
     (range) 
 
39.57 
(36.7 - 41.4) 
 
40.14 
(36.4 - 41.5) 
0.083 
Delivery mode 
    spontaneous 
    caesarean section 
    vacuum extraction  
 
11 (64.7) 
4 (23.5) 
2 (11.8) 
 
14 (56.0) 
1 (6.3) 
1 (6.3) 
0.292 
Interruption of supplementation  
    never  
    once 
    twice 
    more than twice & longer than 2 days 
 
11 (64.7) 
3 (17.6) 
3 (17.6) 
0 (0.0) 
 
13 (81.3) 
 2 (12.5) 
1 (6.3) 
0 (0.0) 
0.512 
Tolerance 
    very good 
    good 
    not so good  
    bad 
 
8 (47.1) 
7 (41.2) 
1 (5.9) 
1 (5.9) 
 
11 (68.8) 
3 (18.8) 
2 (12.5) 
0 (0.0) 
0.337 
Complaints  
    yes 
    no 
 
7 (41.2) 
10 (58.8) 
 
5 (31.3) 
11 (68.7) 
0.554 
    Intensity of complaints 
        good to bear 
        bearable 
        almost unbearable  
        unbearable  
 
4 (23.5) 
2 (11.8) 
1 (5.9) 
0 (0.0) 
 
2 (12.5) 
1 (6.3) 
2 (12.5) 
0 (0.0) 
0.717 
    Duration of complaints 
        short 
        up to 1 hour 
        more than one hour 
        the whole day 
 
2 (11.7) 
1 (5.8) 
3 (17.6) 
1 (5.8) 
 
2 (12.5) 
2 (12.5) 
0 (0) 
1 (6.3) 
0.500 
Stool irregularities 
    yes 
    no 
 
8 (47.1) 
9 (52.9) 
 
13 (81.3) 
3 (18.7) 
0.188 
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Newborn 
Prebiotic 
(n=18) 
Placebo 
(n=17) 
P 
Gender1  
    girl 
    boy 
 
8 (44.4) 
10 (55.6) 
 
8 (47.1) 
9 (52.9) 
0.615 
APGAR (5 min) 
    median  
    (range) 
 
10 
(10 - 10) 
 
10 
(10 - 10) 
1.00 
APGAR (10 min) 
    median  
    (range) 
 
10 
(10 - 10) 
 
10 
(10 - 10) 
1.00 
Umbilical pH 
    n2 
    median  
    (range) 
 
18 
7.34 
(7.1 - 7.4) 
 
16 
7.34 
(7.2 - 7.4) 
0.511 
Birth weight (g) 
    median  
    (range) 
 
3368 
(2345 - 4080) 
 
3370 
(2590 - 3855) 
0.947 
Birth length (cm) 
    median  
    (range) 
 
51.0 
(47.0 - 54.0) 
 
52.0 
(49.0 - 64.0) 
0.127 
Table 9. Study population at delivery. 1Results are expressed as median (range) for continuous variables 
and numbers of subjects (%) for dichotomous variables. 2Numbers of subjects (n) are only indicated when they 
differ from the total number of subjects in each group. Differences between both groups were calculated with 
MWU test for continuous data or χ2 test for dichotomous data. 
 
Vaginal pH values remained stable at an acidic pH of around four during the supplementation 
period and no significant difference was observable between the prebiotic and placebo 
supplemented group (Figure 9). 
Although stool consistency seemed to become softer towards study end in the prebiotic group, 
no significant differences were observed between both groups (data not shown). The stool 
frequency (Figure 10) and the regurgitation frequency (data not shown) did not differ 
significantly between both groups.  
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Figure 9. Average vaginal pH values in the prebiotic and placebo group during the 
supplementation period. Data are shown as box plots (black bar: median, boxes: inter-quartile range (IQR), 
T-bars: range,* and o : outliers). Differences between both groups at each time point were assessed using MWU 
test. Differences within one group over time were assessed using Friedmans test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Average stool frequency per day in the prebiotic and placebo group during the 
supplementation period. Data are shown as box plots (black bar: median, boxes: IQR, T-bars: range, * and o 
: outliers). Differences between both groups at each time point were assessed using MWU test. Differences 
within one group over time were assessed using Friedmans test. 
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4.2.3 Follow-up interview 
 
A follow-up interview was carried out with 30 participants (16 from the prebiotic group and 
14 from the placebo group) and data were obtained from 17 and 15 infants, respectively. 
Contact to three women (one woman from the prebiotic and two women from the placebo 
group) and their children was lost. No statistically significant differences concerning feeding 
habits were observed between both supplementation groups (Table 10). In the first three days 
of life all neonates were breast fed and only three neonates (two from the prebiotic and one 
from the placebo group) received additional formula milk.  
 
Infant 
Prebiotic 
(n=17) 
Placebo  
(n=15) 
P 
Breast milk in the first 3 days1 
    yes 
    no 
 
17 (100) 
0 (0.0) 
 
15 (100) 
0 (0.0) 
1.000 
Formula milk in the first 3 days 
   yes 
    no 
 
2 (11.8) 
15 (88.2) 
 
1 (6.7) 
14 (93.3) 
0.621 
Breast milk in the first 6 months 
    yes 
    no 
 
17 (100) 
0 (0.0) 
 
14 (93.3) 
1 (6.7) 
0.279 
Formula milk in the first months 
    yes 
    no 
 
6 (35.3) 
11 (47.8) 
 
3 (20.0) 
12 (80.0) 
0.337 
Exclusive breast feeding at the moment 
    yes, exclusively  
    yes, but not exclusively 
    no 
 
2 (15.4) 
11 (84.6)  
4 (23.5) 
 
2 (16.7) 
10 (88.3)  
3 (20.0) 
0.968 
Solid foods 
    n2 
    yes 
    no 
 
15 
12 (80.0) 
3 (20.0) 
 
13 
13 (100) 
0 (0.0) 
0.088 
Atopic eczema in the first 6 months 
    yes 
    no 
 
2 (12.8) 
15 (88.2) 
 
0 (0.0) 
15 (100) 
0.170 
Antibiotic treatment in the first 3 weeks 
    yes 
    no 
 
3 (17.6) 
14 (82.4) 
 
1 (6.7) 
14 (93.3) 
0.349 
Antibiotic treatment in the last 5 months 
    yes 
    no 
 
2 (11.8) 
15 (88.2) 
 
0 (0.0) 
17 (100) 
0.145 
Table 10. Feeding habits, atopic eczema and antibiotics in the first 6 months of life. 
Data were assessed retrospectively in an interview. 1Results are expressed as numbers of subjects (%). 
Differences between both groups were calculated with χ2 test. 2 Numbers of subjects (n) are only indicated when 
they differ from the total number of subjects in each group. 
 
 
  RESULTS 
   35
Similarly all infants from the prebiotic group and 93.3% of the infants from the placebo group 
predominantly received breast milk in the first six months of their life. 35.3% of the infants in 
the prebiotic group and 20% of the infants in the placebo group received additional formula 
milk. After half a year, two infants from each group were still exclusively breast fed. Most 
infants had already started taking supplementary food. Two participants from the prebiotic 
reported an atopic eczema (confirmed by a doctor’s diagnosis) in their infants at the age of 
three and five months, respectively. Two mothers from the prebiotic group reported that their 
infants received antibiotics during the last five months due to an infection. Cephachlor was 
given to one neonate for 10 days at the age of four weeks and Clarithromycin was given to 
another neonate for seven days at the of age six weeks. 
 
4.3 Analyses of stool samples 
 
A total of 33 maternal stool samples (17 from the prebiotic and 16 from the control group) 
were collected before supplementation start (before the 25th week of gestation). 
After supplementation (shortly before expected delivery) 31 stool samples (17 from the 
prebiotic and 14 from the placebo group) were obtained: two samples from the placebo group 
were not immediately frozen after collection and had to be excluded from analyses.  
From the 35 neonates (one gemini in each supplementation group) 33 stool samples (17 from 
the prebiotic and 15 from the placebo group) were collected at day 5: one participant from 
each group was unable to collect any faecal sample from the baby because the sample was 
completely sucked up into the diaper. Thirty four neonatal stool samples (18 from the 
prebiotic and 16 from the placebo group) were collected at day 20: one participant from the 
placebo group forgot to immediately freeze the neonatal sample after collection. Additionally, 
one neonatal sample from day 20 form the placebo group did not contain enough material. 
After half a year (~ day 182) 32 neonatal stool samples (17 from the prebiotic and 15 from the 
placebo group) were collected: three neonatal stool samples (one from the prebiotic group and 
two from the placebo group) were not available due to loss of contact to participants. 
Collected samples were analysed by FISH and qPCR. The percentage of bifidobacteria and 
lactobacilli as determined by FISH and qPCR analyses showed no statistical differences. Data 
from both quantification methods (qPCR versus FISH) correlated significantly with each 
other [correlation for bifidobacteria > 0.904 and for lactobacilli > 0.942; p<0.001; Spearman 
Rho]. 
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 4.3.1 Maternal stool samples 
 
Maternal baseline stool pH values (i.e. at the 25th week of gestation) did not differ 
significantly [p=0.564; MWU] between both intervention groups (Figure 11). Prebiotic 
supplementation was not associated with significantly increased stool pH values as compared 
to baseline [p=0.619, paired Wilcoxon] and as compared to placebo [p=0.905; MWU]. No 
significant difference between both groups was observed in the change of stool pH (∆ stool 
pH) from before to after supplementation [p=0.592; MWU]. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. PH values in maternal stool samples before study start (before) and after 
supplementation (after) in the prebiotic and placebo supplemented group. The difference in 
stool pH before and after supplementation is shown as ∆ stool pH. Data are shown as box plots 
(black bar: median, boxes: IQR, T-bars: range, o : outliers). Differences between both groups were assessed using 
MWU test. Differences within one group before and after supplementation (intra-group comparisons) were 
assessed with paired Wilcoxon test.  
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At study entry, the total number of bacteria (as determined by DAPI) in the maternal samples 
was significantly lower [p=0.017; MWU] in the prebiotic group as compared to placebo 
(Figure 12). Prebiotic supplementation was not associated with significantly increased 
bacterial numbers as compared to study entry [p=0.227; paired Wilcoxon] and to the placebo 
group [p=0.427; MWU]. A significant increase [p=0.029; MWU] in the change of total 
bacterial counts (∆ total bacterial count) was observed in the prebiotic group as compared to 
the placebo group.  
 
 
 
 
 
 
 
 
  
Figure 12. Total bacterial counts in maternal stool samples before and after supplementation 
in the prebiotic and placebo group (determined by DAPI). The difference in total bacterial 
counts before and after supplementation is shown as ∆ total count. Data are shown as box plots 
(black bar: median, boxes: IQR, T-bars: range, * and o : outliers). Differences between both groups were assessed 
using MWU test. Differences within one group before and after supplementation (intra-group comparisons) were 
assessed with paired Wilcoxon test. 
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The absolute numbers of bifidobacteria or lactobacilli (bacteria/mL) were determined from 
the percentage of bifidobacteria or lactobacilli (from qPCR analyses) and the total counts of 
bacteria (if available). Baseline bifidobacteria numbers per g faeces (bacteria/mL) were 
significantly lower [p=0.014; MWU] in the prebiotic group as compared to placebo (Figure 
13). Prebiotic supplementation significantly increased the numbers of bifidobacteria/mL as 
compared to baseline [p=0.001: paired Wilcoxon] but not as compared to placebo [p=0.122; 
MWU]. A significant increase [p=0.024; MWU] in the change of absolute bifidobacteria 
numbers (∆ bifidobacteria/mL) was observed in the prebiotic group as compared to the 
placebo group.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Absolute numbers of bifidobacteria (bacteria/mL) in maternal stool samples before 
and after supplementation in the prebiotic and placebo supplemented group (determined by 
qPCR). The difference in absolute numbers of bifidobacteria (bacteria/mL) before and after 
supplementation is shown as ∆ bifidobacteria/mL. Data are shown as box plots (black bar: median, 
boxes: IQR, T-bars: range, * and o : outliers). Differences between both groups were assessed using MWU test. 
Differences within one group before and after supplementation (intra-group comparisons) were assessed with 
paired Wilcoxon test.  
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No statistical significant difference [p=0.476; MWU] between both supplementation groups 
was observed when analysing the numbers of lactobacilli per g faeces (bacteria/mL) at study 
start in maternal stool samples (Figure 14). Prebiotic supplementation had no effect on the 
numbers of lactobacilli (bacteria/mL) as compared to study start [p=0.75; paired Wilcoxon] 
and to placebo [p=0.224; MWU]. No difference in the change of absolute lactobacilli 
numbers (∆ lactobacilli/mL) was observed in the prebiotic group as compared to the placebo 
group [p=0.512; MWU]. 
  
 
 
 
 
 
  
 
 
 
 
Figure 14. Absolute numbers of lactobacilli (bacteria/mL) in maternal stool samples before 
and after supplementation in the prebiotic and placebo supplemented group (determined by 
qPCR). The difference in absolute numbers of lactobacilli (bacteria/mL) before and after 
supplementation is shown as ∆ lactobacilli/mL. Data are shown as box plots (black bar: median, boxes: 
IQR, T-bars: range, o : outliers). Differences between both groups were assessed using MWU test. Differences 
within one group before and after supplementation (intra-group comparisons) were assessed with paired 
Wilcoxon test. 
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Baseline percentages of bifidobacteria within total bacteria did not differ significantly 
[p=0.105; MWU] between both supplementation groups in the maternal samples (Figure 15). 
At study end, the percentage of bifidobacteria were significantly higher in the prebiotic group 
as compared to study start [p<0.001; paired Wilcoxon] and as compared to the placebo group 
[p=0.026; MWU]. Both results were confirmed by FISH analyses [p=0.009 and p=0.008, 
respectively]. Similarly, a significant increase [p=0.011; paired Wilcoxon] in the difference of 
percentages of bifidobacteria (∆ % bifidobacteria) was observed in the prebiotic group as 
compared to the placebo group. This result was confirmed by FISH analyses [p<0.001]. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Percentages of bifidobacteria within total bacteria in maternal stool samples before 
and after supplementation in the prebiotic and the placebo group. The difference in 
percentages of bifidobacteria (%) before and after supplementation is shown as ∆ % 
bifidobacteria. Data are shown as box plots (black bar: median, boxes: IQR, T-bars: range, o : outliers). 
Differences between both groups were assessed using MWU test. Differences within one group before and after 
supplementation (intra-group comparisons) were assessed with paired Wilcoxon test.  
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Baseline percentages of lactobacilli within total bacteria did not differ significantly [p=0.139; 
MWU] between both supplementation groups in the maternal samples (Figure 16).  
Prebiotic supplementation had no effect on the percentages of lactobacilli as compared to 
study start [p=0.210; paired Wilcoxon] and to placebo [p=0.370; MWU]. These results were 
confirmed by FISH analyses. No difference in the change of percentages of lactobacilli (∆ % 
lactobacilli) was observed in the prebiotic group as compared to the placebo group [p=0.953; 
MWU]. This result was confirmed by FISH analyses. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Percentages of lactobacilli within total bacteria in maternal stool samples before 
and after supplementation in the prebiotic and the placebo group. The difference in percent of 
lactobacilli (%) before and after supplementation is shown as ∆ % lactobacilli. Data are shown as 
box plots (black bar: median, boxes: IQR, T-bars: range, * and o : outliers). Differences between both groups 
were assessed using MWU test. Differences within one group before and after supplementation (intra-group 
comparisons) were assessed with paired Wilcoxon test. 
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L. acidophilus, L. paracasei and L. fermentum were the species most commonly characterized 
in maternal stool samples, before and after supplementation, in two groups. Before 
supplementation begin higher percentages of L. casei [p=0.038; χ2] and L. paracasei 
[p=0.019; χ2] were observed in the prebiotic group as compared to the placebo group. This 
was confirmed by higher percentages of L. casei [p=0.042; MWU] and L. paracasei 
[p=0.015; MWU] as determined by qPCR analyses in the prebiotic group as compared to the 
placebo at study start. However, these differences were not significant upon taking multiple 
testing into consideration. Taken together, prebiotic supplementation had no detectable effect 
on maternal bifidobacterial and lactobacilli microbiota as compared to baseline (intra-group 
comparison) and as compared to placebo (inter-group comparison).  
Mother Prebiotic Placebo 
% of subjects  
positive for  
before 
(n=17) 
after 
(n=17) 
before 
(n=16) 
after 
(n=14) 
B. adolescentis 29.4 47.1 37.5 50.0 
B. angulatum 11.8 17.6 18.8 26.6 
B. animalis 11.8 23.5 0.0 0.0 
B. bifidum 17.6 23.5 25.0 42.9 
B. breve 35.3 a 35.3 6.3 a 42.9 
B. catenulatum 70.6 70.6 50.0 64.3 
B. dentium 5.9 0.0 6.3 0.0 
B. infantis 58.8 70.6 56.3 71.6 
B. longum 23.5 11.8 6.3 7.1 
L. acidophilus 58.8 76.5 31.3 42.9 
L. casei 23.5 b 5.9 0.0 b 0.0 
L. delbrueckii 11.8 35.3 12.5 21.4 
L. fermentum 35.3 11.8 18.8 35.7 
L. paracasei 41.2 c 41.2 6.3 c 14.3 
L. plantarum 0.0 0.0 18.8 21.4 
L. reuteri 11.8 17.6 0.0 7.1 
L. rhamnosus 11.8 17.6 18.8 14.3 
Table 11. Percentage of mothers positive for specific bifidobacterial and lactobacilli species. 
Bacteria were quantified in maternal stool samples taken before and after supplementation. 
Differences between the prebiotic and placebo supplemented group were calculated by χ2 test (a p=0.04,b 
p=0.038,c p=0.019; not significant after correction for multiple testing). Differences between both sampling time 
points within one supplementation group were calculated by McNemar test. 
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4.3.2 Neonatal stool samples 
 
Baseline neonatal stool sample pH values at day 5 did not differ significantly [p=0.179; 
MWU] between both groups (Figure 17). Prebiotic intervention was not associated with 
increased stool pH values at day 20 or after half a year (~ day 182) as compared to baseline 
[p=0.407 or p=0.256; paired Wilcoxon] and as compared to placebo [p=0.574 or p=0.737; 
MWU]. A significant increase was observed when comparing pH values from day 20 with 
day 182 in the prebiotic group [p=0.024; paired Wilcoxon]. Caesarean delivery is known to 
influence the composition of the neonatal gut microbiota. Therefore, an analysis where infants 
born by caesarean delivery were excluded from analyses (five from the prebiotic and one 
from the placebo group) was performed. After exclusion of neonates born by caesarean 
sections the difference between day 20 and day 182 in the prebiotic was no longer present. No 
difference in the change of stool pH (∆ stool pH) was observed in the prebiotic group as 
compared to the placebo group at the respective time points [p=0.249; p=0.874 and p=0.299 
respectively; MWU] (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. PH values in neonatal stool samples from day 5, day 20 and day 182 in the 
prebiotic and placebo supplemented group. Data are shown as box plots (black bar: median, boxes: IQR, 
T-bars: range, o : outliers). Differences between both groups were assessed using MWU test. Differences within 
one group before and after supplementation (intra-group comparisons) were assessed with paired Wilcoxon test. 
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The total numbers of bacteria (DAPI) in neonatal stool samples did not differ significantly 
between both supplementation groups at day 5 [p=0.805; MWU], day 20 [p=0.154; MWU] 
and day 182 [p=0.728; MWU], (Figure 18). Differences in total counts and intra-group 
comparisons over time were not determined due to too small numbers of matching pairs for 
statistical analyses.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure18. Total bacterial counts in neonatal stool samples from day 5, day 20 and day 182 in 
the prebiotic and placebo supplemented group (determined by DAPI). Data are shown as box plots 
(black bar: median, boxes: IQR, T-bars: range, * and o : outliers). Differences between both groups were assessed 
using MWU test.  
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The absolute numbers of bifidobacteria or lactobacilli (bacteria/mL) were determined from 
the percentages of bifidobacteria or lactobacilli (from qPCR analyses) and the total counts of 
bacteria (if available). Baseline bifidobacteria numbers per g faeces (bacteria/mL) at day 5 did 
not differ significantly [p=0.110; MWU] between both groups (Figure 19). Significantly 
lower numbers of bifidobacteria (bacteria/mL) were observed at day 20 in the prebiotic group 
as compared to the placebo group [p=0.027; MWU]. After excluding neonates born by 
caesarean sections the difference seen between the prebiotic and the placebo group was no 
longer present. No statistical significant difference between both supplementation groups was 
observed for the numbers of bifidobacteria (bacteria/mL) at day 182 [p=0.870; MWU]. 
Differences in absolute numbers of bifidobacteria (∆ bifidobacteria/mL) before and after 
supplementation and intra-group comparisons over time were not determined due to too small 
numbers of matching pairs for statistical analyses. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. Absolute numbers of bifidobacteria (bacteria/mL) in neonatal stool samples from 
day 5, day 20 and day 182 in the prebiotic and placebo supplemented group (determined by 
qPCR). Data are shown as box plots (black bar: median, boxes: IQR, T-bars: range, o : outliers). Differences 
between both groups were assessed using MWU test.  
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At day 5 the prebiotic supplemented group showed significantly higher numbers of 
lactobacilli (bacteria/mL) [p=0.043; MWU] as compared to the placebo supplemented group 
(Figure 20). After exclusion of neonates born by caesarean sections this difference was no 
longer present. No significant differences between both groups were observed in samples 
taken at day 20 [p=0.058; MWU] and day 182 [p=0.213; MWU]. 
Differences in absolute numbers of lactobacilli (∆ lactobacilli/mL) before and after 
supplementation and intra-group comparisons over time were not determined due to too small 
numbers of matching pairs for statistical analyses. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. Absolute numbers of lactobacilli (bacteria/mL) in neonatal stool samples from day 
5, day 20 and day 182 in the prebiotic and placebo supplemented group (determined by 
qPCR). Data are shown as box plots (black bar: median, boxes: IQR, T-bars: range, * and o : outliers). 
Differences between both groups were assessed using MWU test.  
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The analyses of the percentage of bifidobacteria within total bacteria at the three different 
time points revealed no significant difference [p=0.072; p=0.376, p=0.925 MWU; 
respectively] between both supplementation groups (Figure 21). Within the prebiotic group a 
significant increase [p=0.010; paired Wilcoxon] in the percentage of bifidobacteria was 
observed when comparing day 5 with day 182. This effect was only seen in the percentages of 
bifidobacteria determined by qPCR but not by FISH analyses. In addition, this difference was 
no longer present after exclusion of neonates born by caesarean sections.  
 
 
 
 
 
 
 
 
 
 
 
Figure 21. Percentages of bifidobacteria within total bacteria in neonatal stool samples from 
day 5, day 20 and day 182 in the prebiotic and the placebo supplemented group. Data are shown 
as box plots (black bar: median, boxes: IQR, T-bars: range). Differences between both groups were assessed 
using MWU test. Differences within one group before and after supplementation (intra-group comparisons) were 
assessed with paired Wilcoxon test.  
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day 182 [p=0.454; MWU]. Samples from day 20 tended to be a bit higher in the prebiotic 
group as compared to the placebo group [p=0.049; MWU]. This effect was only seen in the 
percentages of lactobacilli determined by qPCR but not by FISH analyses. In addition, this 
difference was no longer present after exclusion of neonates born by caesarean sections. Intra-
group comparisons showed significantly higher percentages of lactobacilli at day 5 as 
compared to day 20 [p=0.012; paired Wilcoxon] in the prebiotic group determined by qPCR. 
This effect was not confirmed by FISH analyses and was no longer present after exclusion of 
neonates born by caesarean section. In addition, a significant increase in the numbers of 
Prebiotic Placebo
0
20
40
60
80
100
%
  b
ifi
do
ba
ct
er
ia
Neonatal stool samples
5        20    ~182
17       18      17 
5       20     ~182
16     15        15 
day
n =
p=0.010
%
  b
ifi
do
ba
ct
er
ia
  RESULTS 
   48
lactobacilli was observed in the placebo group [p=0.037; paired Wilcoxon] when comparing 
day 20 with day 182. This effect was confirmed by FISH analyses [p=0.020; paired 
Wilcoxon] and remained after excluding the children born by caesarean section [p=0.038; 
paired Wilcoxon]. 
 
 
 
 
 
 
 
 
 
Figure 22. Percentages of lactobacilli within total bacteria in neonatal stool samples from day 
5, day 20 and day 182 in the prebiotic and the placebo supplemented group. Data are shown as 
box plots (black bar: median, boxes: IQR, T-bars: range, * and o : outliers). Differences between both groups 
were assessed using MWU test. Differences within one group before and after supplementation (intra-group 
comparisons) were assessed with paired Wilcoxon test.  
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children born by caesarean sections [p=0.016; McNemar] but could not be confirmed by 
qPCR analyses and [p=0.110; paired Wilcoxon]. It however, must be kept in mind that these 
differences were not significant upon taking multiple testing into consideration. 
Neonate Prebiotic Placebo 
% of subjects 
positive for  
Day 5 
(n=17) 
Day 20 
(n=18) 
Day 182 
(n=17) 
Day 5 
(n=16) 
Day 20 
(n=15) 
Day 182 
(n=15) 
B. adolescentis 11.8 16.7 11.8 31.3 20.0 13.3 
B. angulatum 5.9 0.0 0.0 12.5 13.0 0.0 
B. animalis 5.9 0.0 0.0 0.0 0.0 0.0 
B. bifidum 29.4 50.0 35.3 56.3 50.0 46.7 
B. breve 76.5 77.8 82.4 75.0 66.7 50.0 
B. catenulatum 47.1 38.9 23.5 37.5 20.0 6.7 
B. dentium 0.0 0.0 0.0 0.0 0.0 0.0 
B. infantis 100 77.8 76.5 100 86.7 93.3 
B. longum 25.0 27.8 29.4 25.0 13.3 20.0 
L. acidophilus 52.9 a 27.8 41.2 18.8a 13.3 b 66.7 b 
L. casei 17.6 16.7 29.4 6.3 6.7 20.0 
L. delbrueckii 0.0 0.0 0.0 6.3 0.0 0.0 
L. fermentum 35.3 22.2 11.8 12.5 13.3 26.7 
L. paracasei 52.9 27.8 29.4 81.3 6.7 33.3 
L. plantarum 17.6 11.1 5.9 6.3 0.0 0.0 
L. reuteri 5.9 0.0 5.9 0.0 0.0 0.0 
L. rhamnosus 0.0 0.0 0.0 0.0 0.0 0.0 
Table 12. Percentage of neonates positive for specific bifidobacterial and lactobacilli species. 
Bacteria were quantified in neonatal stool samples taken at day 5, day 20 and day 182. 
Differences between the prebiotic and placebo supplemented group were calculated by χ2 test (a p=0.04; not 
significant after correction for multiple testing). Differences between the three sampling time points day 
(bp=0.016) within one supplementation group were calculated by McNemar test. 
 
4.3.3 Microbiota in maternal & neonatal samples 
 
4.3.3.1 Diversity index 
 
Maternal stool samples after, but not before, supplementation showed a significantly higher 
bifidobacterial diversity as compared to lactobacilli diversity in the prebiotic group [p=0.039; 
paired Wilcoxon]. In contrast, the diversity of bifidobacteria was higher in the placebo group 
both before and after supplementation [p=0.020; paired Wilcoxon]. Similarly, the neonates of 
both groups showed a significantly higher diversity of bifidobacteria species than lactobacilli 
species at all analysed time points [p<0.016; paired Wilcoxon]. Maternal stool samples 
showed no differences in bifidobacterial and lactobacilli diversity in relation to the 
intervention group, either before or after supplementation begin (Table 13). Similarly, the 
samples taken from infants at day 5, day 20 and day 182 exhibited no significant differences 
in bifidobacterial and lactobacilli diversity between both groups (Table 13). When assessing 
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the samples from the mothers before supplementation begin with the samples from infants at 
day 5, significant differences in the bifidobacterial diversity were found in the placebo group 
[p=0.006; paired Wilcoxon] but not in the prebiotic supplemented group [p=0.163; paired 
Wilcoxon]. For both groups, no differences were found in the bifidobacterial diversity when 
comparing maternal samples before supplementation begin with neonatal samples at day 20, 
and when comparing maternal samples after supplementation with neonatal samples at days 5, 
20 and 182, respectively (Table 13). In both groups, no significant differences in the 
lactobacilli diversity were found when comparing maternal samples before supplementation 
begin with neonatal samples from day 5. In contrast, significant differences were observed in 
both groups when comparing the diversity indices from maternal samples before 
supplementation with neonatal samples from day 20 [p=0.043 and p=0.035 respectively; 
paired Wilcoxon] and day 182 in the prebiotic group [p=0.033; paired Wilcoxon].  
 Bifidobacteria Lactobacilli 
Diversity index (%) 
 
Prebiotic Placebo P Prebiotic Placebo P 
Mother before 
    n 
    median1 
     (range) 
 
17 
22 
(11 - 77) 
 
16 
22 a 
(11 - 44) 
0.272  
17 
25 b, g 
(0 - 50) 
 
16 
0 c 
(0 - 50) 
0.055 
Mother after 
    n 
    median 
     (range) 
 
17 
22 
(11 - 77) 
 
14 
33 
(11 - 55) 
0.670  
17 
22 e 
(0 - 44) 
 
14 
22 d,f 
(0 - 44) 
0.289 
Infant day 5 
    n 
    median 
     (range) 
 
17 
33 
(11 - 66) 
 
16 a 
33 
(22-55) 
0.520  
17 
37 
(0 - 50) 
 
16 
0 d 
(0 - 63) 
0.123 
Infant day 20 
    n 
    median 
     (range) 
 
18 
27 
(0 - 55) 
 
15 
33 
(0 - 55) 
0.897  
18 
0 b,e 
(0 - 44) 
 
15 
0 c,f 
(0 - 33) 
0.125 
Infant ~ day 182 
    n 
    median 
     (range) 
 
17 
33 
(0 - 55) 
 
15 
33 
(11 - 55) 
0.983  
17 
0 g 
(0 - 44) 
 
15 
22 
(0 - 33) 
0.658 
Table 13. Bifidobacterial and lactobacilli diversity indices in mothers receiving prebiotic or 
placebo supplementation and their infants. Maternal stool samples were taken before and after 
supplementation and neonatal stool samples were taken at day 5, day 20 and day 182. The 
bacterial diversity index was calculated using the following formula DI = (A/B) x 100, with A 
representing the number of species detected in a sample and B representing the total number 
of analysed species (n=9 bifidobacteria and n=8 lactobacilli). 1Results are expressed as median 
(range). Differences between both supplementation groups were calculated with MWU test. Differences between 
maternal-infant samples within one supplementation group were calculated with paired Wilcoxon test. Identical 
superscripts indicate significant differences (a p=0.006, b p= 0.043, c p= 0.035, d p= 0.046, e p= 0.030, f p= 0.008, g 
p=0.033). 
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The comparison of the samples from the mothers after supplementation with the samples from 
the infant at day 5 revealed significant differences in lactobacilli diversity in the placebo 
group [p=0.046; paired Wilcoxon]. In both the prebiotic and the placebo group, the 
comparison of the samples from the mothers after supplementation with the samples from the 
infant at day 20 revealed significantly higher values in maternal samples [p=0.030, p=0.008; 
paired Wilcoxon].  
 
4.3.3.2 Correlations 
 
The analysis of the species correlating in maternal samples after supplementation with 
neonatal samples from day 5, day 20 and day 182 revealed no correlation for B. breve, B. 
dentium, B. infantis, B. longum, L. paracasei and L. rhamnosus. In contrast, a significant 
correlation between maternal samples after supplementation and neonatal samples from day 5 
was observed in both groups for B. adolescentis, B. angulatum, B. bifidum, B. catenulatum 
and L. fermentum (Table 14). B. animalis, B. catenulatum and L. reuteri correlated only in the 
prebiotic group, while B. infantis and B. plantarum correlated only in the placebo group at 
day 5. The correlation of L. fermentum remained in both groups up to day 20 and in the 
prebiotic group up to day 182. The correlation between maternal samples after 
supplementation and neonatal samples at day 5 observed for B. adolescentis remained up to 
day 20 and day 182 in the prebiotic group. At day 182, a correlation was found in the 
prebiotic group for B. bifidum and L. reuteri. In the placebo group, only B. infantis correlated 
in neonatal samples from day 182 with maternal samples after supplementation. When 
comparing maternal samples after supplementation with neonatal samples from day 5, the 
total number of correlating species was identical in the prebiotic (n=7) as compared to the 
placebo supplemented group (n=7, Table 14). The total number was reduced in the prebiotic 
group (n=2) and in the placebo group (n=6) after exclusion of neonates born by caesarean 
sections (data not shown). The total number of species correlating in maternal samples after 
supplementation and neonatal samples from day 20 decreased in the prebiotic (n=2) and the 
placebo group (n=1) as compared to day 5 (Table 14), but remained the same after excluding 
the children born by caesarean sections (data not shown).  
Similarly, the total number of species correlating in maternal samples after supplementation 
and neonatal samples from day 182 was decreased in the prebiotic (n=4) and the placebo 
group (n=1) as compared to day 5 (Table 14). After exclusion of caesarean section born 
infants, the number was further reduced in the prebiotic group (n=1) and in the placebo group 
(n=0, data not shown). 
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Correlation of 
species 
Mother after - 
Infant day 5 
Mother after - 
Infant day 20 
Mother after - 
Infant ~ day 182 
as determined 
by qPCR 
Prebiotic Placebo Prebiotic Placebo Prebiotic Placebo 
B. adolescentis 
    Correlation1 
    P 
 
0.509 
0.036 
 
0.735 
0.001 
0.500 
0.034 
  
0.516 
0.003 
 
B. angulatum 
    Correlation 
    P 
 
0.613 
0.008 
 
0.643 
0.009 
    
B. animalis 
    Correlation 
    P 
 
0.537 
0.026 
     
B. bifidum 
    Correlation 
    P 
 
0.692 
0.002 
 
0.586 
0.021 
   
0.512 
0.035 
 
B. catenulatum 
    Correlation 
    P 
 
0.559 
0.019 
 
0.599 
0.018 
    
B. infantis 
    Correlation 
    P 
  
0.651 
0.008 
    
0.515 
0.049 
L. delbrueckii 
    Correlation 
    P 
      
L. fermentum 
    Correlation 
    P 
 
0.491 
0.045 
 
0.546 
0.035 
 
0.661 
0.002 
 
0.575 
0.031 
0.637 
0.005 
 
L. plantarum 
    Correlation 
    P 
  
0.619 
0.013 
    
L. reuteri 
    Correlation 
    P 
 
0.613 
0.008 
    
0.613 
0.008 
 
Total number 
of correlating 
species 
7 7 2 1 4 1 
Table 14. Infant-mother correlations for specific bifidobacterial and lactobacilli species (as 
determined by qPCR) in mothers receiving prebiotic or placebo supplementation. Correlations 
were determined between samples after supplementation in mothers and at day 5 in children, 
after supplementation in mothers and at day 20 in children, as well as after supplementation in 
mothers and at day 182 in infants. 1Correlations were calculated by Spearman rank test.  
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4.3.3.3 Similarity index 
 
The similarity indices for bifidobacteria, lactobacilli, as well as bifidobacteria plus lactobacilli 
obtained from maternal samples before supplementation with neonatal samples from days 5, 
day 20 and day 182 did not differ significantly between both groups (data not shown). No 
differences between both supplementation groups were observed when comparing the 
similarity indices of bifidobacteria, lactobacilli or bifidobacteria and lactobacilli from 
maternal samples after supplementation with samples from the infant at day 5, day 20 or day 
182, respectively (Table 15). Overall the bifidobacterial similarity indices were higher in both 
the prebiotic and placebo supplemented group as compared to the lactobacilli similarity 
indices.  
 
Mother after - 
           infant day 5            
Mother after – 
         infant day 20          
Mother after - 
      infant ~ day 182         
Similarity 
index (%) 
Prebiotic Placebo P Prebiotic Placebo P Prebiotic Placebo P 
Bifidobacteria 
    n 
    median1 
    (range) 
 
17 
50 
(0-100) 
 
15 
60 
(25-
100) 
0.176  
18 
33 
(0-100) 
 
14 
55 
(0-100)
0.349  
17 
33 
(0-75) 
 
15 
40 
(0-100)
0.223
Lactobacilli 
    n 
    median 
    (range) 
 
17 
0 
(0-75) 
 
10 
0 
(0-100)
0.622  
18 
0 
(0-75) 
 
9 
0 
(0-100)
0.764  
16 
0 
(0-75) 
 
14 
0 
(0-67) 
0.777
Bifidobacteria 
& lactobacilli 
    n 
    median 
    (range) 
 
 
17 
40 
(0-82) 
 
 
15 
43 
(20-83)
 
0.134
 
 
18 
23 
(0-73) 
 
 
14 
38 
(0-75) 
 
0.312
 
 
17 
25 
(0-75) 
 
 
15 
29 
(0-67) 
 
0.383
Table 15. Infant-mother bifidobacterial, lactobacilli and bifidobacterial plus lactobacilli 
similarity indices (%) obtained for samples taken from the mothers after delivery and from the 
infants at day 5, day 20 and day 182 in the prebiotic and placebo supplemented group.  
SI = (C/D) x 100, with C representing the number of mother-infant species that matched, i.e. 
that were detectable in both mother and infant and D representing the number of all species 
which were either positive in the mother, the infant or both. 1Results are expressed as median 
(range). Differences between both supplementation groups were calculated with MWU test.  
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4.4 Analyses of CB samples  
 
4.4.1 Flow cytometry data 
 
From the 35 neonates 30 EDTA CB samples (16 from the prebiotic group and 14 from the 
placebo group) were collected immediately after delivery: no EDTA CB samples were 
available from the three placebo supplemented women, who delivered at other hospitals. In 
addition, two CB tubes from the prebiotic group did not contain enough material for 
performing the flow cytometric analyses. All obtained samples were analysed by flow 
cytometry. Samples from antibiotic treated babies (n=5, 3 from the prebiotic and 2 from the 
placebo group) were retrospectively excluded from statistical analyses, so that 25 samples (13 
from the prebiotic group and 12 from the placebo group) were included in the statistical 
analyses. 
 
4.4.1.1 Chemokine receptor expression on CD4+ & CD8+ T cell subsets 
 
CB cells were labelled with anti-CD4, anti-CD8 (to distinguish naive T helper from cytotoxic 
T cells), anti-CD45-RA (to distinguish naive from memory T cells) and antibodies directed 
against different chemokine receptors (CKRs). The CD4+/CD8+ ratio did not differ 
significantly [p=0.647; MWU] between the prebiotic group (median: 3.6; range: 1.0 - 7.8) and 
the placebo group (median: 3.5; range: 1.3 - 12.8). 
CD4+ and CD8+ cells were predominantly found to be naïve expressing CD45RA+ cells, while 
only a very small subset expressed the CD45RO+ memory marker. The frequency of 
CD45RA+ or CD45RO+ expressing CD4+ or CD8+ T cells did not differ between both 
supplementation groups (Table 16).  
 CD4+ T cells CD8+ T cells 
 Prebiotic 
(n=13) 
Placebo 
(n=12) 
P Prebiotic 
(n=13) 
Placebo 
(n=12) 
P 
% CD45RA1 
   median  
   (range) 
 
83.8 
(62.7 - 95.8) 
 
85.3 
(79.4 - 97.3) 
0.242  
91.2 
(83.3 - 98.5) 
 
92.95 
(78.5 - 99.5) 
0.399
% CD45RO 
   median  
   (range) 
 
13.2 
(4.0 - 37.3) 
 
12.8 
(0.0 - 20.6) 
0.149  
8.8 
(1.5 - 16.7) 
 
7.05 
(0.5 - 15.2) 
0.221
Table 16. Frequency of CD45RA+ and CD45RO+ expressing cells within the CD4+ and CD8+ 
CB T cell population in the prebiotic and placebo group. 1Results are expressed as median (range). 
Differences between both groups were calculated with MWU test.  
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To address the potential of chemokine responsiveness of CB T cells, the cell surface 
expression of different CKRs was examined within CD4+ and CD8+ T cell subsets. The 
frequency of CKR+ expressing CD4+ CB T cells revealed no significant differences between 
both supplementation groups (Figure 23). Overall the frequency of CCR1, CCR2, CCR5, 
CCR6, CCR8, CCR9, CRTH2, CXCR5 expressing CD4+ T cells was low (< 1%). In contrast, 
the frequency of CCR4 and CXCR3 expressing CD4+ T cells was slightly higher (< 6%). 
Consistent with their known tropism for secondary lymphoid tissues through high endothelial 
venules, most CD4+ naive T cells expressed CCR7 (median of both groups 94.9%) and 
CXCR4 (median of both groups 100%). Since CXCR4 expression was heterogeneously 
spread through the lymphocyte gate, the MFI of CXCR4 on CD4+ was analysed. No 
significant difference [p=0.055; MWU] was observed between the prebiotic (median: 1340; 
range: 1048 - 3162) and the placebo group (median: 2139; range: 609 - 18165) for the MFI of 
CXCR4+ on CD4+.cells. 
 
 
 
 
 
 
 
 
 
 
 
Figure 23. Frequency of CKR+ expressing cells within the CD4+ CB T cell population in the 
prebiotic and placebo group. Data are shown as box plots (black bar: median, boxes: IQR, T-bars: range, * 
and o : outliers). Differences between both groups were calculated with MWU test. 
 
The analyses of the frequency of CKR+ expressing CD8+ CB T cells showed no significant 
differences between both groups (Figure 24). The frequency of CCR1, CCR2, CCR4, CCR5, 
CCR6, CCR8, CCR9, CRTH2, CXCR5 expressing CD8+ T cells was low (< 5%) as compared 
to CCR7 (median of both groups 88.3%) and CXCR4 (median of both groups 100%).  
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The MFI of CXCR4+ on CD8+ T cells showed no significant difference between the prebiotic 
(median: 3187; range: 1731 - 6369) and the placebo supplemented group (median: 4656; 
range: 916 - 31750). The MFI of CXCR4 was significantly higher on CD8+ T cells than on 
CD4+ T cells [p<0.001; paired Wilcoxon].  
Apart from CCR4 and CCR7, which were expressed at higher frequencies on CD4+ T cells, 
all other CKRs were expressed at significantly higher frequencies on CD8+ T cells [p<0.003; 
paired Wilcoxon]. CXCR3 was expressed at a higher frequency on CD8+ T cells (median of 
both groups 82.6%) than on CD4+ T cells [p<0.001; paired Wilcoxon]. A subset analyses 
revealed, that CXCR3 was mainly found on naïve CD8+ T cells (71.6% of the CD8+CD45RA+ 
cells expressed CXCR3).  
 
 
 
 
 
 
 
 
 
 
Figure 24. Frequency of CKR+ expressing cells within the CD8+ CB T cell population in the 
prebiotic and placebo group. Data are shown as box plots (black bar: median, boxes: IQR, T-bars: range, * 
and o : outliers). Differences between both groups were calculated with MWU test.  
 
A further subset analyses of the frequency of CKR+ expressing CD4+CD45RA+ and CD8+ 
CD45RA+ T cells revealed no significant differences between both groups (data not shown).In 
order to determine whether a Th2 bias is present in CB the ratios of Th1:Th2 associated CKRs 
were calculated within the CD4+ and CD8+ subsets. The ratios of CXCR3:CCR4, 
CXCR3:CCR8, CCR5:CCR4 and CCR5:CCR8 revealed no significant differences between 
both groups (Table 17).  
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 CD4+ T cells CD8+ T cells 
Th1:Th2 
ratio 
Prebiotic 
(n=13) 
Placebo 
(n=12) 
P Prebiotic 
(n=13) 
Placebo 
(n=12) 
P 
CXCR3:CCR4 
median 
(range) 
 
0.56 
(0.21 - 1.55) 
 
0.58 
(0.35 - 3.30) 
0.786  
47.07 
(4.79 - 219.25)
 
43.32 
(16.03 - 233.0)
0.389
CXCR3:CCR8 
median 
(range) 
 
6.00 
(2.08 - 
25.00) 
 
8.77 
(0.90 - 43.0) 
0.807  
68.64 
(8.34 - 219.67)
 
17.15 
(2.19 - 285.67)
0.176
CCR5:CCR4 
median 
(range) 
 
0.09 
(0.00 - 1.36) 
 
0.14 
(0.04 - 0.75) 
0.142  
1.13 
(0.05 - 7.50) 
 
2.54 
(0.2 - 8.71) 
0.295
CCR5:CCR8 
median 
(range) 
 
1.00 
(0.00 - 8.00) 
 
1.83 
(0.11 – 18.0)
0.463  
1.02 
(0.5 - 35.00) 
 
0.51 
(0.09 - 9.89) 
0.156
Table17. Th1:Th2 ratio on CD4+ and CD8+ CB T cells in the prebiotic and placebo group. 
Differences between both groups were calculated with MWU test.  
 
4.4.1.2 CD25high expression on CD4+ T cell subsets 
 
The analyses of the frequency of CD25high expressing CD4+, CD4+CD45RA+ and 
CD4+CD45RO+ T cell subsets revealed no significant differences between both groups 
(Figure 25). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25. Frequency of CD25high expressing cells within different CD4+ subsets of CB T 
cells in the prebiotic and placebo group. Data are shown as box plots (black bar: median, boxes: IQR, T-
bars: range, * and o : outliers). Differences between both groups were calculated with MWU test.  
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The frequency of the early expression marker CD69+ on CD4+ T cells was low in both the 
prebiotic group (median: 0.2; range: 0.0 - 0.4) and the placebo group (median: 0.3; range 0.0 - 
1.0) [p=0.488; MWU].  
 
4.4.1.3 TLR2+ & TLR4+ expression on CD14+ monocytes 
 
The MFI of CD14+ monocytes showed no significant difference [p=0.050; MWU] between 
the prebiotic group (median: 3906, range: 2911 - 7408) and the placebo group (median: 5501; 
range: 2090 - 9959). The MFI of TLR2+ was higher [p=0.019; MWU] in the placebo group, 
while TLR4+ was equally expressed in both groups (Figure 26). However, upon taking into 
multiple testing into consideration, this difference was not significant.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26. MFI of TLR2+ and TLR4+ on CD14+ CB monocytes in the prebiotic and placebo 
group. Data are shown as box plots (black bar: median, boxes: IQR, T-bars: range, o : outliers). Differences 
between both groups were calculated with MWU test.  
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4.4.2 Multiplex array data 
 
From 35 neonates, 29 Li-Heparin CB samples (16 from the prebiotic group and 13 from the 
placebo group) were immediately collected after delivery: no CB samples tubes were 
available for the stimulation assay from the three placebo supplemented mothers, who 
delivered at other hospitals. In addition, two CB tubes from the prebiotic group and one from 
the placebo group did not contain enough material for performing the stimulation assay. All 
samples were analysed. Samples from antibiotic treated babies (n=5, three from the prebiotic 
and two from the placebo group) were retrospectively excluded from the analyses. Two 
further CB samples from the placebo group had to be excluded from statistical analyses 
because of high background cytokine concentrations in the negative control. Background 
could have been caused by cross-contamination of the stimuli on the plate adjacent to the well 
containing the negative control. In all other cases, CB cells which were not stimulated over 
the culture period (negative control) showed no or very low cytokine expression (background 
responses). Twenty two CB culture supernatants (13 from the prebiotic and 9 from the 
placebo group) were included in the statistical analyses.  
For all stimuli, IL-2 concentrations were based on the number of lymphocytes (pg/mL/10E3 
leukocytes), while all other analyzed cytokines were based on the number of leukocytes 
(pg/mL/10E3 lymphocytes). The concentrations of IL-5, IL-7, IL-12, IL-13 and IL-15 were 
low or below detection limit regardless of the stimuli used (data not shown). TNF-α, IFN-γ, 
IL-1β, IL-2, IL-4, IL-10, GM-CSF, G-CSF concentrations in the supernatants were directly 
measured without further dilution, while IL-6, IL-8, IL-10, MCP-1, MIP-1ß supernatants were 
diluted 1:10.  
 
4.4.2.1 Cytokine expression in Der p1, BLG, LPS & OVA stimulated samples 
 
The analyses of the cytokines IL-1ß, IL-4, IL-10, IFN-γ, TNF-α, GM-CSF, G-CSF revealed 
that Der p1, as well as BLG, OVA and LPS induced similar cytokine expression patterns after 
24 h. Der p1, BLG, OVA, and LPS showed approximately equal amounts of IL-1β and G-
CSF, comparably lower amounts of IL-10, IFN-γ, TNF-α, GM-CSF and very low 
concentrations of IL-2 and IL-4 (Figure 27). Except for G-CSF, which was expressed at 
higher levels in the Der p1 [p= 0.012; MWU], BLG [p=0.03; MWU] and OVA [p=0.008; 
MWU] stimulated samples from prebiotic group, all other analysed cytokines revealed no 
significant differences between both supplementation groups. However, upon taking multiple 
testing into consideration, these differences were not significant.
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Figure 27. Cytokine expression levels after stimulation of whole CB samples from the 
prebiotic and the placebo group with Der p1, BLG, LPS, OVA for 24 h. For IL-1ß, G-CSF, 
IL-10, IFN-γ, TNF-α, GM-CSF and IL-4 concentrations are shown in pg/mL/10E3 leukocytes 
and for IL-2 in pg/mL/10E3 lymphocytes. Data are shown as box plots (black bar: median, boxes: IQR, 
T-bars: range, * and o : outliers).  Differences between both groups were calculated with MWU test. 
 
IL-6 was induced at very high concentrations in Der p1, BLG, LPS and OVA stimulated 
samples (Figure 28), whereas IL-8, MCP-1 and MIP-1ß were induced at much lower levels 
after 24 h. Samples from both supplementation groups revealed no significant differences 
after 24 h. 
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Figure 28. Cytokine expression levels (pg/mL) after stimulation of whole CB samples from 
the prebiotic and the placebo group with Der p1, BLG, LPS, OVA for 24 h. For IL-6, IL-8, 
MIP-1ß and MCP-1 concentrations are shown in pg/mL/10E3 leukocytes. The numbers in 
parentheses reflect the number of samples with cytokine concentrations above detection limit 
(not used as data for statistical calculation). Data are shown as box plots (black bar: median, boxes: 
IQR, T-bars: range, * and o : outliers). Differences between both groups were calculated with MWU test. 
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4.4.2.2 Cytokine expression in Con A & SEB stimulated samples 
 
Con A and SEB were potent IL-2 inducers in contrast to Der p1, BLG, LPS and OVA, which 
did not induce IL-2 after 24 h (Figure 29). The highest IL-2 concentrations were detected in 
Con A stimulated samples, while IFN-γ, GM-CSF, G-CSF, IL-1β, IL-10 and TNF-α were 
induced at lower levels. SEB induced only low amounts of IL-2 and none of the other 
cytokines. No significant differences were observed between both supplementation groups 
after 24 h. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29. Cytokine expression levels (pg/mL) after stimulation of whole CB samples from 
the prebiotic and the placebo group with Con A and SEB for 24 h. For IL-1ß, G-CSF, IL-10, 
IFN-γ, TNF-α, GM-CSF and IL-4 concentrations are shown in pg/mL/10E3 leukocytes and 
for IL-2 in pg/mL/10E3 lymphocytes. Data are shown as box plots (black bar: median, boxes: IQR, T-
bars: range, * and o : outliers).  Differences between both groups were calculated with MWU test. 
 
IL-6, MIP-1ß and IL-8 were induced at lower or similar levels in Con A stimulated samples as 
compared to samples stimulated with Der p1, BLG, LPS and OVA after 24 h (Figure 30).  
In comparison to SEB and all other stimuli, Con A induced the highest amounts of MCP-1. 
From all stimuli, SEB induced the lowest IL-6, IL-8, MCP-1 and MIP-1ß concentrations after 
24 h. No differences were observed between both supplementation groups after 24 h. 
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Figure 30. Cytokine expression levels (pg/mL) after stimulation of whole CB samples from 
the prebiotic and the placebo group with Con A and SEB for 24 h. For IL-6, IL-8, MIP-1ß and 
MCP-1 concentrations are shown in pg/mL/10E3 leukocytes. Data are shown as box plots (black 
bar: median, boxes: IQR, T-bars: range, * and o : outliers). Differences between both groups were calculated with 
MWU test. 
 
For the calculation of the Th1:Th2 ratio, IL-4 concentrations below detection limit were set to 
1.0 pg/mL. The ratio of INF-γ to IL-4 (Th1:Th2) calculated for each cytokine showed no 
significant differences between both groups (data not shown). Supernatants from the 48 h 
stimulation assay were not further analysed. 
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5. DISCUSSION  
 
This double-blind randomised placebo-controlled pilot intervention study (with 33 
participants) investigated the effects of prebiotic supplementation during the last trimenon of 
pregnancy on the maternal gut and vaginal microbiota. In addition, the influence on the 
neonatal gut colonization and selected foetal immune parameters was assessed. 
Self-assessment based questionnaires were used to determine the overall long-term 
acceptance and tolerance of prebiotic supplementation during pregnancy. Supplementation of 
pregnant women with 3x3 g of prebiotics (GOS/FOS : 9/1) per day was well tolerated. No 
apparent adverse effects were observed. As expected, abdominal discomfort (flatulence, 
constipation, diarrhoea, reflux) was reported rarely and only by a few participants. 
Only a few double-blind placebo-controlled human trials with prebiotics have been conducted 
so far and a direct comparison with other intervention studies was not possible due to 
differences in prebiotic preparations (FOS, GOS, neosugar, inulin), doses and duration of 
supplementation, study participants and study design. Nevertheless, our results are in 
accordance with studies in human adults, which have shown that intake doses of prebiotics in 
the range of 4-15 g per day for 2 to 5 weeks [86, 87] were generally well tolerated by healthy 
adult participants, while intake doses as high as 30 g/day (0.5 g/kg) have been associated with 
gastrointestinal side effects, in particular flatulence [131]. 
 
5.1 Microbiota analyses  
 
5.1.1 Maternal vaginal pH 
 
Previous studies have found that the vagina is normally protected by lactobacilli. Lactobacilli 
maintain an acidic environment and produce substances (e.g. lactic acid, hydrogen peroxide 
and bacteriocins) that inhibit the activity of other microorganisms. Bacterial vaginosis is one 
of the most common infections that occurs in pregnant women [132]. It is associated with an 
elevated vaginal pH (more than 4.5) and an altered vaginal microbiota. Bacterial vaginosis is 
characterized by a decrease of the normally predominant lactobacilli species and an increase 
in potentially pathogenic anaerobic, facultative and gram negative microorganisms (e.g. 
Candida, Gardnerella, Mycoplasma, Ureoplasma, Streptococcus species and E. coli). Studies 
have shown that bacterial vaginosis can lead to a two-fold increased risk of preterm labour 
and spontaneous abortion [132, 133]. The balance can be restored with antibiotics, by direct 
application of probiotic lactobacilli (L. rhamnosus GR-1, L. fermentum B-45 and RC-14) into 
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the vagina or by oral consumption of lactobacilli containing fermented dairy products [134, 
135]. However, according to a PubMed search (containing the terms: clinical study, 
prebiotics, inulin, oligofructose and bacterial vaginosis, vaginal pH; from 1996-2006), no 
studies on the effects of oral prebiotic supplementation on vaginal pH (restoration or 
stabilization of pH values) have been conducted so far. The concept of vaginal pH self-
measurement using gloves to screen for disturbances in the vaginal milieu during pregnancy 
has previously been shown to efficiently prevent prematurity [136].  
Throughout the intervention study, we observed no significant differences in self-assessed 
vaginal pH values between the prebiotic and the placebo supplemented group. Since no 
vaginal fluid samples were collected and analysed, no conclusions on the numbers of 
lactobacilli and consequently on a potential stabilization of the vaginal microbiota can be 
drawn. 
 
5.1.2 Maternal stool samples 
 
During the study period, no effects of prebiotic supplementation on bowel habits including 
stool frequency and consistency, as well as stool pH were observed. 
Some intervention studies with prebiotics reported stimulation of colonic motility and 
decrease of transit time [137], normalization of stool consistency (relief of constipation or 
loose stool) [84], increase of stool weight [86], and decrease of pH in faecal slurry cultures 
[85], while others found no changes in stool pH, as well as stool frequency [88, 138]. 
These conflicting data might be attributed to differences in daily prebiotic intake, study 
population and duration of supplementation period. However, in general OF and inulin have 
been shown to have few effects on bowel habits of adults, other than increasing output [139]. 
Since faecal output and SCFA were not measured in our study, we can draw no conclusions 
on the effects of prebiotics on stool weight and SCFA profiles. In addition, no food protocols 
were collected. Therefore, it is not clear, whether the lack of prebiotic effect on stool 
frequency and consistency was due to changes in life style, including diet and fluid intake, 
(e.g. magnesium, folate or iron pills and laxative consumption) or due to general changes of 
intestinal motility and physical inactivity connected to pregnancy. 
It is becoming increasingly clear that there is considerable variation between individuals with 
respect to both the diversity of the colonic microbiota [140] and the response of the 
microbiota to prebiotic consumption [141]. The total counts and the basal numbers of 
bifidobacteria per g faeces (bacteria/mL) differed significantly between both supplementation 
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groups before study begin, while the numbers of lactobacilli were very similar. The results of 
total counts determined by DAPI staining are in good agreement with values obtained by 
other investigators [142]. On the other hand, considerable variations have been observed 
when comparing our results with culturable total counts. Culturable total counts are often 
mentioned in intervention studies [86] and have been reported to be 5-10 times lower than the 
total cell counts [125, 142] as determined by DAPI. These variations may be explained by 
differences in media and cultivation methods (aerobe or anaerobe conditions), as well as 
differences in detection sensitivity (conventional plating techniques versus the currently 
available modern culture independent molecular based detection methods). Differences (∆) in 
total bacterial counts (DAPI) and numbers of bifidobacteria (bacteria/mL as well as % of total 
bacteria) determined by qPCR were significantly higher in the prebiotic supplemented group 
than in the placebo group. This was confirmed by an increase of the bifidobacterial numbers 
in total bacterial load as determined by FISH. In contrast, we observed no changes in the 
numbers (bacteria/mL) and the percentages of lactobacilli (determined by qPCR and FISH). 
Our results agree with a number of in vitro [85] and in vivo studies using OF [12, 84]. Intake 
doses of FOS, which have elicited a bifidogenic effect in adults, ranged from 4 to 15 g/day 
(i.e. 0.05 - 0.11 g/kg/day) and were already observed after 2 to 5 weeks, independent of chain 
length or GOS or FOS type [84, 86-88]. Gibson et al. [86] showed that supplementation of 15 
g OF/day to strictly controlled diets of healthy adults for 15 days caused a significant increase 
in the mean viable counts of bifidobacteria, but not of lactobacilli. Interestingly, the numbers 
of bifidobacteria declined significantly, when OF was withdrawn, indicating that the increase 
was transient and directly attributable to the addition of OF to the diet. In addition, OF had 
little effect on the total viable counts of aerobes and anaerobes. Roberfroid et al. [41] reported 
that the degree of prebiotic stimulus is in part dependent on the initial amount of the 
endogenous probiotic flora and that there is no clear dose-effect relationship in term of log 
increases of bifidobacterial counts in the human gut after FOS supplementation. He showed 
that the lower the initial number of bifidobacteria the greater the increase (whatever the daily 
dose, within a range of 4-20 g or more) [41] and stated that only one log-fold increase in 
bifidobacteria can be considered as an indication for a modification of the intestinal flora. 
However, since faecal counts of bifidobacteria vary considerably within the general 
population (from 10E7 to 10E9), such dose-effect relationships are difficult to observe [41].  
We found considerable inter- and intra-individual differences in microbial bifidobacteria and 
lactobacilli composition in both supplementation groups. This is in agreement with 
observations made by other investigators, who analysed 16S RNA fingerprints and found that 
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the predominant bacterial community of each individual was host specific and stable [10, 
140]. Similarly, high fluctuations in the species and strain composition, as well as the 
numbers over time, have been shown by others, reporting that the relative proportions can 
vary considerably in time depending on the individual [142-144]. Despite the inter- and intra-
individual variations, no indications for a change in bifidobacterial and lactobacilli 
composition at a single species level (inter-group comparisons and intra-group comparisons) 
were observed. This indicates a stronger impact of the indigenous microbiota and shows that 
the microbiota in adults remains rather constant, despite changes in dietary intake. 
Before supplementation B. catenulatum, followed by B. infantis and B. adolescentis were the 
most frequent species in maternal samples in both groups of our study. The percentages were 
determined according to Liu et al. [128]. Due to different quantification techniques, direct 
comparisons of our results with data from other studies were not possible. However, the 
overall proportions of enumerated bifidobacteria were consistent with the current knowledge 
obtained by both culture and molecular-based methods, showing that in most adults the 
bifidobacterial community is a combination of one to four species: B. adolescentis, B. longum, 
B. catenulatum and B. bifidum [145, 146]. For example, He F. et al. [147] analysed 
bifidobacterial species composition in healthy adults and identified 51 bifidobacterial strains, 
most belonging to the species B. adolescentis, B. breve, B. infantis and B. longum. In contrast, 
B. longum, B. catenulatum and B. adolescentis were the most commonly characterized species 
in a study with healthy Japanese adults [142]. The same species were also observed in a study 
with Finnish pregnant women [148]. The observed heterogeneity may be attributed to 
different quantification methods or nutritional and lifestyle habits, as well as genetic and 
environmental differences. Therefore, caution should be taken when interpreting the results, 
especially, when it comes to strain and species numbers.  
Identification of lactobacilli by traditional plating culture methods is known to be more 
difficult, as compared to bifidobacteria, and enumeration has been shown to depend on plating 
techniques e.g. selective culture media and incubation conditions [149]. Lactobacilli 
constitute less than 1% of the total bacterial community and considerable variability in the 
numbers and species of lactobacilli has been shown between individuals [15]. L. acidophilus 
was the species most commonly characterized in both groups, before and after 
supplementation, followed by L. paracasei, L. fermentum and L. casei. Consistent with our 
results, L. acidophilus, L. casei and L. fermentum, but also L. salivarius, L. plantarum, and L. 
reuteri have been shown to be typical representatives which can be isolated from human 
intestine [15, 146]. 
  DISCUSSION 
   68
Overall, we found a significant increase in bifidobacterial numbers in the prebiotic 
supplemented group. The faecal samples from mothers receiving prebiotic supplementation 
showed a large variety of bifidobacterial and lactobacilli species, but the profiles were very 
similar to that of the control group. The levels of the different species showed that long-term 
prebiotic supplementation (with 9 g GOS/FOS per day in a ratio of 9:1) did not selectively 
stimulate the growth of one particular species in the intestinal microbiota. However, effects of 
prebiotics on other predominant genera in the large bowel, including Clostridium-Coccoides-
Eubacterium group, Bacteroides group or Atopobium cluster, were not analysed. In addition, 
it should be noted that our picture has been biased in favour of the analysed Bifidobacterium 
and Lactobacillus species detectable by FISH and qPCR primers and that many other species 
are still unknown [7, 140]. 
 
5.1.3 Neonatal stool samples 
 
Trials in which prebiotic supplementation has been evaluated in infants differed from ours in 
study design and study population. To our knowledge, most trials with prebiotics directly 
supplemented term or preterm infants for a certain time period and compared the microbiota 
with that of infants fed standard formula [118-120, 150]. Only a few studies included 
breastfed children as a control group [126, 127, 151, 152]. Since all neonates in our study 
were breastfed, we searched for studies, which included breastfed infants as a control group in 
their investigations. However, due to different sampling time points and quantification 
techniques, direct comparisons of our results with data from other studies were not possible. 
Neonatal stool pH ranged between 5.6 - 6.1 and showed no significant differences between 
both groups, when analysing samples taken at day 5, day 20 and after half a year. In 
accordance, stool pH from three month old breastfed infants was shown to range around of 
5.8 [152]. Changes in neonatal stool frequency and consistency were not assessed; therefore 
no conclusions on bowel behaviour can be drawn from our study.  
For a long time it was assumed that the maternal vagina is the source of the bacteria [23, 25] 
that initially colonize the neonatal GIT. However, plasmid profiling showed that lactobacilli 
inhabiting the maternal vagina did not colonize the infant digestive tract [20]. Evidence for 
the transmission of faecal isolates of the bifido- and enterobacteria from the mother to the 
infant exist. There are indications that the faeces at 10 days after birth would contain bacteria 
that had truly colonized the digestive tract of the infant [20]. 
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In our study, total bacterial counts, numbers of bifidobacteria and lactobacilli (bacteria/mL), 
as well as the percentages of bifidobacteria and lactobacilli, revealed no significant 
differences between both groups, at day 5, day 20 and day 182 after exclusion of children 
born by caesarean sections. Due to different stool sampling time points in other studies a 
direct comparison of our data was not possible. For example, one supplementation study 
found 67.6+4.1% of bifidobacteria in the breastfed infant group at the age of three months 
using FISH analyses [152]. In another study, the percentages of bifidobacteria in exclusively 
breastfed infants aged 28-90 days were 63.3+7.7% and increased to 90.3+3.6% after a six 
week follow-up using both FISH and qPCR analyses [126]. Similarly, the percentages of 
lactobacilli increased from 0.8+0.3 to 4.1+1.5% [127] after six weeks. In our study, the 
analyses of the percentages of subjects positive for a certain bifidobacterial or lactobacilli 
species showed that B. infantis followed by B. breve, B. catenulatum, B. bifidum and B. 
longum were not only the most prevalent bifidobacteria species characterized at day 5 and day 
20 in both groups, but also the bifidobacterial species that occurred at the highest percentages 
(% qPCR). Similarly, L. paracasei, L. acidophilus and L. fermentum were among the most 
prevalent strains detected at day 5 and day 20. No significant differences were found between 
both groups, except for the percentages of subjects positive for L. acidophilus at day 5. 
However, this result was not confirmed by qPCR analyses. After half a year, the most 
frequent isolated stains were B. infantis, B. breve, L. acidophilus and L. paracasei, while B. 
angulatum, B. animalis, B. dentium, L. delbrukeii and L. rhamnosus were never found.  
These results are in agreement with Haarman et al. [126, 127], who reported that B. infantis, 
B. breve and B. longum, as well as L. acidophilus and L. paracasei  were the most dominant 
species in one to three month old breastfed infants. In addition, B. bifidum, as well as L. 
reuteri, L. gasseri, L. rhamnosus and L. fermentum are also commonly present in infants 
[153]. However, our data are in contrast to a recent Finnish study by Gueimonde et al. 
analysing the bifidobacterial species composition in infants and their mothers [148]. In this 
study, pregnant women received LGG or placebo for four weeks before and three weeks after 
delivery. Stool samples were taken from the mother before supplementation and at study end. 
In addition, stool samples from the infants were collected at day 5 and day 21. B. adolescentis 
(~ 30.8%), B. infantis, B. longum and B. catenulatum (all 15.4%) were reported to be the most 
frequently detected species at day 5, while B. longum (~ 25%) and B. breve, B. bifidum and B. 
adolescentis (~ 12.5%) were found to be the most frequent detected strains after 21 days in 
the breastfed placebo group. Lactobacilli were not assessed in this study.  
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Our results are also in contrast to data published by Ahrne S. et al. [149], who found L. 
rhamnosus to be the most common isolated lactobacilli strain (~ 21%) in six-month old 
breastfed Swedish children. In both studies methodological differences (detection sensitivity 
of the applied analyses method), country dependent differences and genetic variations may 
have contributed to the observed differences in neonatal microbiota. Favier et al. [154] studied 
the molecular succession of bacterial communities in neonates using denaturing and 
temperature gel gradient electrophoresis (DGGE, TGGE) and showed a colonization by 
bifidobacterial species on the 3rd to 4th day of life. The profiles during the first few days of life 
were simple but became more complex as the bacterial diversity increased with time. 
Streptococcus and Enterococcus species were mainly found during the breast feeding period, 
while the colonization of Ruminococcus and Clostridium or Enterobacter species was 
strongly dependent on the time point of formula introduction, milk withdrawal and solid food 
introduction. Similarly, Sakata et al. [155] reported that the intestine was first colonized by 
enterobacteria and streptococci in term infants in the first few days, while bifidobacteria 
became dominant at day four. Since other bacterial strains were not analysed in our study, we 
cannot draw any conclusions about differences in the overall bacterial community. Gronlund 
et al. [26] found that the faecal bifidobacterial colonization of infants born by caesarean 
delivery was delayed. Bifidobacterium-like bacteria and Lactobacillus-like bacteria 
colonization rates reached the rates of vaginally delivered infants at one month and 10 days, 
respectively. Infants born by caesarean delivery were also significantly less often colonized 
with bacteria of the Bacteroides fragilis group than vaginally delivered infants [25, 26, 156]. 
Due to the small sample size of the infants born by caesarean sections (five infants from the 
prebiotic group versus one from the placebo group), we did not further analyse and compare 
the bacterial colonization patterns of this subgroup with vaginally delivered infants. 
 
5.1.4 Comparison of maternal & neonatal microbiota  
 
The diversity index of bifidobacteria and lactobacilli species in infant samples from day 5, 
day 20 and day 182 did not differ significantly between both groups. To our knowledge no 
comparable study analysing both bifidobacteria and lactobacilli diversity indices has been 
published thus far. In our study, the numbers of bifidobacteria at all analysed time points were 
significantly higher than the numbers of lactobacilli in both groups. This is in accordance with 
studies showing that bifidobacteria dominate over lactobacilli in this age group [157, 158].  
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We observed that in both supplementation groups the lactobacilli diversity index, but not 
bifidobacterial diversity index, was significantly higher in maternal samples taken shortly 
before delivery, as compared to infant samples collected at day 20. This is in contrast to 
Gueimondes results [148], who only observed in the placebo group a significantly higher 
bifidobacterial diversity when comparing maternal stool samples taken after delivery and 
neonatal stool samples taken at day 21. However, it must be stated that a direct comparison 
with our data with Gueimondes data [148] was not possible due to differences in 
supplementation (prebiotic GOS:FOS supplementation in our study versus probiotic LGG 
supplementation in Gueimondes study). 
The analyses of the total number of species correlating in maternal stool samples after 
supplementation with neonatal samples at day 5 revealed no significant differences between 
the prebiotic and the placebo group. At day 20 the total number of correlating species was 
lower as compared to day 5 and tended to be slightly higher in the prebiotic group than in the 
placebo group. We found no indications that the prebiotic-induced bifidobacterial 
colonization of the maternal intestine affected the colonization of the infant. This is in contrast 
to results published by Schultz et al. [159], who showed that pregnant women consuming 
LGG capsules during the last weeks of their pregnancy specifically conferred the strain to 
their vaginally delivered children. Interestingly, LGG was not only detectable at the age of 
one month but was also found to colonize the infant at the age of six months. Similarly, 
Gueimode et al. [148] found significant correlations in the breastfed placebo group for B. 
adolescentis, B. longum and B. catenulatum when comparing maternal samples taken three 
weeks after delivery with neonatal stool samples taken at day 21 from breastfed infants. A 
direct comparison of our data with the data from this study was not possible due to differences 
in the analyses procedure used for determining correlations. While we used the % qPCR data, 
Gueimonde et al. [148] used the % of subjects positive for a species to calculate the 
correlations between maternal and infant samples.  
We found no significant differences between both supplementation groups when comparing 
the similarity index of bifidobacteria and lactobacilli, respectively at any of the time points 
analysed. This is in contrast to Gueimonde et al. [148], who reported significantly higher 
similarity in the placebo, as compared to the LGG group, when analysing stool samples from 
mothers after delivery with neonatal stool samples at three weeks. This similarity was not 
seen when samples taken from the mother before delivery were compared with samples taken 
from the infant at day 5. Again, it must be stated that a direct comparison with our data was 
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not possible due to differences in supplementation (prebiotics versus probiotics) and analyses 
procedures used for determining similarity indices. 
 
Overall, the analyses of neonatal stool composition showed no significant differences between 
both supplementation groups, indicating that neonatal microbiota does not reflect the 
differences induced through prebiotic supplementation in maternal microbiota. This further 
indicates that factors other than the maternal bacterial colonization patterns (e.g. breast 
feeding or physiological and immunological characteristics of the infant) may dominate and 
be more important than the maternal inoculation effect. However, it should be noted that a 
large group of bifidobacteria and lactobacilli species in faecal samples is still unknown and 
that the distribution of these unknown species in neonatal stool might still differ between both 
groups [160]. In addition, no conclusions can be made concerning other bacterial strains 
including Bacteroides, Enterococcus and Clostridium species since these were not analysed in 
neonatal samples. If and to what extent increased maternal bifidobacterial counts could affect 
the colonization of the neonatal gut remains to be determined in further studies. 
 
5.2 CB analyses 
 
Only a few data are available concerning the role of prebiotics in modulating the immune 
system. The few studies that have examined the effects of prebiotic fibres on the immune 
system were conducted in animals (rats, mice, dogs). However, indications for modifications 
of the gut microbiota and thus of the gut-associated lymphoid system are becoming more and 
more evident in animals [82]. As reviewed by Schley et al. [161], prebiotic supplementation 
in animals was associated with increased lymphocyte proliferation and lymphocyte numbers 
in GALT and peripheral blood. Additionally, increases in IgA secretion or IgA cells in GALT, 
decreases in CD4+/CD8+ ratio in spleen and increases in the phagocytic function of intra-
peritoneal macrophages have been reported. So far, only a few human studies have 
investigated the effects of inulin and oligofructose alone, or in combination with other dietary 
supplements, on immune competence. Prebiotic supplementation resulted in minor changes of 
systemic immune functions, such as decreases in phagocytic activity, but no data are available 
on the effects of prebiotics on the GALT in humans [162]. 
One reason why only little attention has been given to the effects of nutritional interventions 
on immune functions is the current lack of a single immune marker to predict the outcome of 
a dietary intervention in humans [163]. The difficulty in choosing the optimal combination of 
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suitable ex vivo and in vivo immune markers in order to assess the effects of nutrition 
intervention studies on the activities of immune key cells, has been discussed in a review by 
Albers et al. [163]. Biological relevance, sensitivity and practical feasibility must be taken 
into consideration when choosing immune function assays. In search for markers detectable at 
birth, numerous investigators analysed umbilical CB to assess the immunologic status of the 
newborn. The methodologies applied in such analyses include the assessment of cellular 
functions by cell culture, measurement of various immunologic mediators in the circulation 
by ELISA and phenotype by flow cytometry. Immune responses have been shown to be Th2 
polarized in the foetus and successively become Th1 dominated in the first year of life [164]. 
Most investigators use CB mononuclear cells (CBMCs) isolated by density gradient 
centrifugation from whole blood for phenotypical and functional characterisation of 
lymphocytes. However, ficoll density centrifugation and extensive washing have been shown 
to remove the cells from their endogenous cytokine and cellular milieu [165], thereby 
affecting T cell function, cytokine production and surface molecule expression [166]. 
Purification techniques may also introduce ex vivo manipulation and give opportunity for 
artefacts. Therefore, it is recommended to reduce experimental manipulation to get accurate 
results reflecting the true in vivo situation. Since numerous investigators have reported 
success using whole blood assays to examine the activation state and the cytokine production 
capacity of various immune cell populations, we undertook an exploratory examination of 
whole CB immune parameters. For the phenotypical characterisation of lymphocytes, we used 
chemokine receptor (CKR) markers as surrogate markers, to screen for different Th1/Tc1 and 
Th2/Tc2 populations in un-stimulated whole CB samples. In addition, we screened for 
changes in the population of cells producing either Th1 or Th2 cytokines using a whole blood 
stimulation assay. 
 
5.2.1 Phenotypical characterisation of CB 
 
Ex vivo phenotypic analyses using multi-parameter flow cytometry can provide information 
on the activation and differentiation status of lymphocytes and their functional properties. 
Several T cell analyses comparing whole blood and purified peripheral blood mononuclear 
cells (PBMC) have shown methodologically different results including variations in the 
CD4+/CD8+ ratios [167] and chemokine receptor expression [168]. Although cryopreserved 
PBMCs [169, 170] are often used in clinical studies for practical reasons, direct analyses of 
whole blood samples is the method of choice, as cells remain largely un-manipulated [171-
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174]. However, two problems of whole blood cultures have been reported in the literature. 
First of all, prevention of correct staining when using whole blood is a potential downside 
associated with this procedure. For instance, soluble cell surface proteins in whole blood may 
interact with marking antibodies. Furthermore, soluble ligands for cell surface proteins may 
prevent antibody binding to the same protein and plasma proteins may interact with the 
peptides used for identification of antigen-specific cells [175]. Secondly, there have been 
conflicting reports about the content and functional properties of CB lymphocytes. 
Discrepancies are influenced by technical factors, including the fact that some investigators 
did not sufficiently exclude NRBCs (potentially as high as 30%) from the lymphocyte gate. 
This may lead to inaccurate estimates of lymphocyte subsets in various reports [174]. 
Additionally, gating strategy and analyses procedure can be a significant source of variability.  
Due to small sample amounts, we decided to study surface molecule expression and cytokine 
production by leukocytes in freshly drawn CB samples and tried to reduce variability by 
standardizing sample processing and analyses procedures. Samples were analysed within 4 h 
after collection. Staining conditions (reagent quality and batches), as well as flow cytometric 
parameter settings were kept identical for all samples. In addition, the analyses procedures 
were kept constant. For some markers (e.g. CXCR4 and TLR2) gating and setting of limits 
varied slightly from sample to sample, so that an individual fine sample analyses was 
required. We set the lymphocyte gate using both the SSC combined with the expression of 
either CD4+ or CD8+. This avoids the problem created by NRBCs since erythrocytes express 
neither CD4+ nor CD8+. A direct comparison of our data with published data was not possible 
due to differences in sample processing (storage conditions) and gating strategy (e.g. surface 
marker expression is often showed as percentage within a lymphocyte population or 
percentage within the CD3+ T cell population instead of percentage within the CD4+ or CD8+ 
populations). We observed a CD4+/CD8+ ratio of 3.55 in whole CB lymphocytes and found 
no significant differences between both groups. This finding is consistent with data published 
by Canto et al. [170], who found a ratio of 3.19 in CBMCs. For a further characterisation of 
the CB T lymphocytes, we analysed the expression of the leukocyte membrane glycoprotein 
CD45 and found no significant differences between both groups. CD45 exists in two different 
isoforms, as determined by mRNA splicing. Primary responses are mediated by unprimed T 
cells expressing CD45RA+, while recall responses are mediated by CD45RO+ expressing cells 
[176]. We observed that most CB lymphocytes cells expressed the CD45RA+ isoform which 
is typical for naïve, unprimed T cells. This is in accordance with data published by Szabolcs 
et al. [174] and by others [170, 173, 177], showing that the majority of the CB T lymphocytes 
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are phenotypically and functionally immature. Correspondingly, only a small portion 
expressed the CD45RO+ memory phenotype. The memory function of the low numbers of 
CD45RO+ T cells found in the foetal circulation remains undetermined [178].  
Previous studies have shown that increasing antigenic exposure from the maternal 
environment by dia-placental [179] and trans-placental passage [164, 180, 181] can lead to 
activation and differentiation of Th0 cell to Th1/Tc1 or Th2/Tc2 cells. Therefore, we analysed 
a broad spectrum of Th1/Tc1- and Th2/Tc2- related CKRs on CD4+ and CD8+ CB T cells. All 
analysed CKRs on CD4+ and CD8+ CB T cells subsets showed no significant differences 
between both groups. Consistent with the observation that Th1/Th2 chemokine receptors are 
mainly expressed on memory T cells [169], we observed little or no CCR1, CCR2, CCR5, 
CCR6, CCR8, CCR9, CRTH2 and CXCR5 expression on CD4+ and CD8+ T cells. In contrast, 
CCR4 was expressed at higher frequencies on CD4+ than on CD8+ T cells. Interestingly, 
CXCR3 was expressed at much lower frequencies on CD4+ than on CD8+ T cells. This is in 
accordance with Campbell et al. [182], who demonstrated that CXCR3 expression in PBMCs 
is heavily restricted to CD4+CD45RO+ cells, while experienced and naïve CD8+ cells 
expressed CXCR3 at similar frequencies. We observed that CCR7 and CXCR4 were 
expressed on the majority of naïve CB T cells. This corresponds with data from the HLDA8 
Workshop panel report [172], showing no expression of CCR1, CCR5 CCR9 on CB CD4+ 
cells, very low CXCR3 frequencies on CD4+ T cells and stated that CXCR4 was always co-
expressed on CD4+ CB T cells. The activation-induced molecule CD69, is known to be 
rapidly up-regulated within hours after antigenic stimulation. Both CD4+ and CD8+ CB T 
cells expressed CD69 at very low levels. No indications for significant differences between 
the two supplementation groups were observed. In accordance with our results, the expression 
of the early activation marker CD69 on CD3+CD4+ and CD3+CD8+ cells from term neonates 
has been shown to be barely detectable [183]. 
A prerequisite to study T reg cells is the selection of CD4+ T cells expressing high levels of 
the late activation marker CD25 [184, 185]. In line with others, we found three subsets of 
CD25 expressing CD4+ CB T cells: CD4+CD25low, CD4+CD25intermediate and CD4+CD25high T 
cells [129]. In opposite to CD4+CD25low and CD4+CD25intermediate T cells fractions, which do 
not exhibit regulatory properties [185, 186], the regulatory function is confined to the 
CD4+CD25high T lymphocytes. The CD4+CD25intermediate T cell subset contains recently 
activated and proliferating T cells, which transiently up-regulate CD25 [187]. We found that 
1.5% of the CD4+ T cells expressed CD25 at high levels. No significant differences were 
observed between both supplementation groups. A further subset analyses showed that 1.2% 
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of the CD4+CD45RA+ and 3.4% of the CD4+CD45RO+ cells expressed CD25 at high levels. 
In human adult peripheral blood 2-3% of the CD4+ T cells are CD4+CD25high T reg cells. 
Although a natural naive T regulatory subset (0.2 - 3.3% Nn T reg) exists [184], most of the T 
reg cells are confined to the CD45RO memory T cell compartment [188] in adults. 
In contrast, the majority of preterm and term CB T reg cells have a naive phenotype [178, 
186] and are able to suppress proliferation of polyclonally activated CD25- (responder) T cells 
in in vitro assays [189]. Differences in gating strategy might explain the different observations 
between our data and that of other groups. For example, Godfrey et al. [190] found that about 
5% of the CB T cells distinctly expressed CD25high, while others found lower levels [184]. 
Similar results were found by Valmori et al. [184], who reported that up to 7% of the total 
CD4+ T cells and that more than 90% of the CD4+CD45RA+ T cells in CB expressed CD25. 
This implies that CD45RA+ naive foetal T reg cells undergo antigen-mediated activation 
during foetal or postnatal development [191]. Isolation of T regs by beads or FACS sorting to 
analyse functional properties (suppressive function) of CB T regs in in vitro assays was not 
possible in our study, due to small samples volumes. 
Since TLRs have been implicated in the recognition of bacterial cell wall products and 
possibly bridge innate and acquired immunity [192], we investigated the expression of TLR2+ 
and TLR4+ on CD14+ monocytes. TLR4 recognizes LPS (lipid A) of Gram-negative bacteria 
with CD14+ being required as an accessory molecule for efficient LPS signalling. In contrast, 
TLR2 signals in response to a wide range of lipopeptides and is believed to be involved in the 
recognition of a wide variety of infectious pathogens and their products including yeast cell 
walls, mycobacteria, whole Gram-positive bacteria, lipoproteins, glycolipids and 
peptidoglucyan [193]. Signaling by TLRs initiates acute inflammatory responses by induction 
of antimicrobial genes and inflammatory cytokines and chemokines [193]. 
We found MFI values of CD14+ on monocytes ranging between 3906 in the prebiotic group 
and 5501 in the placebo group. The MFI of TLR2+ tended to be higher on CD14+ monocytes 
than the MFI of TLR4+. Our findings are in contrast to other studies, although the overall 
tendency is similar (MFI CD14+> TLR2+>TLR4+). For example, Drohan et al. [194] found 
that the MFI of CD14+, TLR2+ and TLR4+ were much lower on un-stimulated whole CB 
monocytes. Similarly, Amoudruz et al. [195] showed that un-stimulated CBMC samples from 
children with mothers having no allergy had much lower CD14+, TLR2+ and TLR4+ MFIs. 
Variations might be explained by differences in antibody sensitivities, sample storage or 
processing. 
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5.2.2 Functional characterisation of CB  
 
The ability of CB cells to proliferate and produce cytokines in response to a variety of 
environmental antigens (e.g. food antigens, LPS and inhalative allergens) has been described 
by many investigators [196-198]. The lack of previous antigenic experience might be, in part, 
responsible for the reduced capacity to respond to antigens [199], as compared to memory or 
effector T cells. In addition, CB responses to allergens indicated that allergen-responsive T 
cells in neonates lacked the fine tuned specificity of adult memory cells [200].  
Although several studies have demonstrated that cytokine concentrations in whole blood 
cultures are comparable to those in PBMC cultures, whole blood assays showed less inter-
assay variability [166]. In addition, preparation techniques have been shown to cause an ex 
vivo alternation of quantitative cytokine mRNA levels (5-9 fold up-regulation of mRNA 
levels from cytokines like IL-2, IL-4, TNF-α) thereby leading to different expression profiles 
in blood samples [201]. Whole blood culture systems can be used as an effective method to 
obtain reliable and consistent information on the status of cells, especially since the true in 
vivo milieu of cytokines, as well as cellular and non-cellular constituents are retained.  
Therefore, we adapted an experimental set up by Miles et al. [130], which can be easily 
applied to field studies for simple and standardized analyses of cytokine responses in small 
amounts of CB samples. The analysis of cytokine concentrations in supernatants in response 
to a specific stimulus is often used to characterize the nature of the T cell immunity. A large 
number of research studies have focused on general activation of cell cultures with mitogens 
like phytohaemagglutinin (PHA), Con A or superantigens to measure cytokine production. 
However, these results only describe an individual’s general immune response. To better 
characterize the immune response to a specific pathogen or allergen, stimulation with an 
antigen-specific for a particular pathogen or allergen can be used. Therefore, we stimulated 
CB cells with a panel of stimuli (mitogen: Con A as a control antigen) and antigens (food and 
inhalative allergens) to determine the responses of CB cells to specific and non-specific 
stimuli. CB was diluted 1/5 in culture medium, since 1/5 and 1/10 dilutions have been shown 
to be optimal and necessary to prevent coagulation and allow cultivation for longer periods of 
time [165, 202]. Pre-aliqouted reagents were used for stimulation to standardize the assay and 
reduce variability. In addition, intra-assay precision was further increased by fast processing 
within 4 h after blood collection. As reviewed by Vignali et al. [203] cytokine production has 
been extensively investigated in the past using diverse assays which detect cytokines on 
different levels. Polymerase chain reaction (PCR) measures cytokines of the messenger 
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ribonucleic acid (mRNA) levels, intra-cellular cytokine staining (ICS) measures intra-cellular 
cytokines levels, enzyme-linked immunospot (EIPSOT) measures cell-associated cytokines, 
enzyme-linked immune assay (ELISA) and multiplex techniques measure extracellular 
cytokine concentrations [203]. Intra-cellular staining (to assess cytokine production on the 
single cell level by flow cytometry) and [3H] thymidine uptake (to measure proliferative 
responses) were not applicable in this study. Therefore, we assessed cytokine concentrations 
in culture supernatants using a multiplex method, which enables the simultaneous detection of 
many cytokines in one measurement and yields similar results to ELISA assays (concerning 
sensitivity and accuracy). However, this method brings along the disadvantage that the 
cellular source of cytokines produced by whole CB cells is not ascertainable. A direct 
comparison of our data with results obtained from other studies was not possible due to 
different experimental conditions: freshly isolated versus cryopreserved CBMCs [199, 204], 
undiluted versus diluted whole blood [130] and modes of activation (different stimuli, stimuli 
concentrations, incubation periods and cytokine detection methods). 
A potential drawback of the whole CB assay is the variable number of leukocytes in whole 
blood culture, which can influence the amounts of detected cytokines. Therefore, we 
normalized the cytokine concentrations to the number of cells (leukocytes or lymphocytes) 
used in the assay. We observed that allergen- and mitogen-induced cytokine production 24 h 
post-stimulation showed typical cytokine expression patterns. The characteristic stimuli-
induced cytokine profile might reflect differences in the cell signalling processes [130]. 
Overall, no significant differences concerning the stimuli-induced cytokine patterns of both 
groups were observed, after determining the concentration of each cytokine as 
pg/mL/leukocyte. As reported by Lagrelius et al. [205], different kinetic patterns can be 
distinguished when detecting cytokine concentrations at different sampling time points (one 
up to seven days) after stimulation with different stimuli: early peaking and then declining; 
early peaking to plateau levels; continuously increasing; and persisting levels. Therefore, it is 
recommended perform measurements when cytokine levels peak. However, finding a single 
time point that could be used to satisfy these criteria for all cytokines and stimuli studied is 
difficult [205]. In accordance with Miles et al. [130], we therefore measured the cytokine 
concentrations after 24 h. Extra-cellular cytokines in the whole blood culture system showed 
very low background levels in un-stimulated cultures. This has also been suggested by other 
groups using whole blood cultures [205]. Our data agree with results obtained by Miles et al. 
[130], who observed that Con A was a very potent IL-2 inducer. However, in contrast to our 
observations, Miles et al. [130] found Con A to be a more potent inducer of IFN-γ and IL-10 
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than IL-2. In accordance to Miles et al. [130], we found that Der p1 induced the highest IFN-γ 
production among the allergens (BLG and OVA) and that Der p1 was a better IL-10 inducer 
than Con A. In contrast, we observed that Der p1 was the most potent IFN-γ inducer of all 
stimuli, while Miles et al. [130] found that Con A induced the highest IFN-γ concentrations. 
As a conclusion, our data agree only partly with the data published by Miles et al. [130]. The 
observed variations could be explained by differences in detection sensitivity (ELISA versus 
Bioplex), data analyses (we normalized our data to the number of leukocytes or lymphocytes 
while Miles et al. [130] reported crude data) or sample processing. While all our samples were 
stimulated within 4 h after blood collection, Miles et al. [130], do not mention the time 
between sample collection and experiment begin. They acknowledge that apoptosis could 
have contributed to the pattern of cytokine appearance in two ways: “first: removal of 
cytokine producing cells by apoptosis” and “second: release of cytosolic components 
including cytokines into the medium”.  
 
On the basis of the analysed immune parameters (CKR expression and cytokine responses 
upon stimulation of CB), we found no indications for any significant differences between both 
groups. This suggests that maternal prebiotic supplementation and subsequent bifidogenic 
alteration of maternal microbiota has no direct measurable effect on foetal immune 
parameters (as determined by phenotype and the reactivity of whole CB to different stimuli). 
However, it should be noted that due to sample size limitations other immune parameters, e.g. 
phagocytic or NK cell activity, were not assessed in this study. 
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5.3 Potential confounders & outlook 
 
Pregnant women were randomised to one of the two study groups so that known and unknown 
confounders should be balanced evenly between the groups. Although, we do not expect to 
have to take confounding factors into account in our analyses, we analysed the distributions of 
several factors to test whether any imbalance occurred. The factors included those related to 
the family (age of parents, socio-economic status, ethnicity, number and age of siblings, 
parental smoking habits, mode of birth, birth weight and duration of breast feeding). We 
found that none of these parameters could have affected our results.  
The fact that no reliable method exists to ensure regular intake of supplementation by 
participants is one weak point of this study. Another important drawback is the size of the 
study population (n=17 per group). However, our pilot study is the first study analysing a 
broad spectrum of immune markers in combination with different bifidobacterial and 
lactobacilli species. Although we found no significant effects on neonatal microbiota and 
foetal immune parameters, it should be noted that the lack of an observed effect on the 
analysed parameters does not allow the conclusion, that there is no effect.  
So far, only one recent placebo-controlled RCT assessed the effect of prebiotic baby formulae 
on the incidence of atopic dermatitis in atopy-predisposed infants [206]. This study found a 
significant reduction of atopic dermatitis in the prebiotic group, as compared to the placebo 
group. However, how prebiotics modulate postnatal immune development by altering gut 
microbiota composition and what possible long-term implications (what potential) this might 
have on primary allergy prevention during pregnancy is unclear at present and needs to be 
assessed further in larger trails. 
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6. SUMMARY  
 
To our knowledge, this is the first long-term, randomised, double-blind, placebo-controlled 
pilot study reporting the effects of prebiotic supplementation during pregnancy on mothers 
and their offspring. Prebiotic supplementation (at the given concentration) in the last trimenon 
of pregnancy was well tolerated and had a bifidogenic effect on the gut microbiota of 
pregnant women. Prebiotic supplementation had no significant effect on the numbers 
(bacteria/mL) or the percentages of lactobacilli within total bacteria and did not affect 
maternal stool frequency and consistency or vaginal pH values. In addition, there were no 
obvious differences between the prebiotic and the placebo supplemented groups concerning 
the neonatal bifidobacterial and lactobacilli microbiota or the screened CB immune 
parameters. Based on our present data, we conclude that direct administration of prebiotics to 
pregnant women cannot be considered as the method of choice to induce a bifidogenic effect 
in the microbiota of breastfed neonates. We assume that an increase of bifidobacteria in the 
neonatal gut can be achieved more effectively by directly supplementing infant formulae with 
prebiotics.  
Therefore we, agree with the statement of the ESPGHAN committee and conclude that as 
long as there are no data on major clinical or long-term benefits (e.g. gastrointestinal 
infection, allergic disease) [121], “no general recommendations can be made on the use of 
prebiotic formulae in infancy”. If and to what extent formulae fed neonates could profit from 
a bifidogenic enriched maternal microbiota remains to be determined. Large multi-centre 
RCT addressing functional important outcomes (e.g. immune or inflammatory modulation) 
with validated clinical outcome measures are necessary in future to validate the importance of 
prebiotics as a prophylactic or therapeutic measure. 
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7. ZUSAMMENFASSUNG 
 
Diese Studie ist die erste, randomisierte, doppel-blinde, placebo-kontrollierte 
Langzeitpilotstudie, welche die Wirkung der Präbiotika-Supplementation während der 
Schwangerschaft auf die Zusammensetzung der mütterlichen und kindlichen Darmmikroflora 
untersucht. Die Präbiotika-Supplementation im letzten Trimenon der Schwangerschaft zeigte 
eine gute Verträglichkeit und einen bifidogenen Effekt auf die Darmflora Schwangerer. Im 
Gegensatz dazu, hatte die Präbiotika-Supplementation keinen signifikanten Einfluss auf die 
Anzahl der Lactobazillen (Bakterien/mL) oder deren prozentualen Anteil an der 
Gesamtdarmmirkoflora. Ein Einfluss auf die mütterliche Stuhlfrequenz bzw. Konsistenz und 
auf die vaginalen pH-Werte war nicht nachweisbar. Die Präbiotika- und die Placebo-
Supplementierten Gruppen unterschieden sich nicht bezüglich der neonatalen Entwicklung 
der Bifidobakterien- und Lactobazillen-Microflora sowie der untersuchten 
Nabelschnurparameter. Aus den vorliegenden Daten schließen wir, dass die mütterliche 
Präbiotika-Supplementation nicht zur Induktion eines bifidogenen Effekts in der Darmflora 
gestillter Kinder empfohlen werden kann. Es ist anzunehmen, dass eine Erhöhung der 
Bifidobakterien im Neugeborenendarm effektiver durch die direkte Supplementation der 
Babynahrung mit Präbioitika erreicht werden kann.  
Aus diesem Grund, schließen wir uns dem Konsens des ESPGHAN Komitees an und 
kommen angesichts des Fehlens von Daten bezüglich wichtiger klinischer Langzeit Vorteile 
durch Präbiotika (z.B. gastrointestinale Infektionen, allergische Erkrankungen) [121], zu dem 
Schluss dass „keine generelle Empfehlung der Supplementation von Babynahrung mit 
Präbiotika“ gegeben werden kann. Ob und in welchem Ausmaß zugefütterte Neugeborene 
von einer mit Bifidobakterien angereicherten mütterlichen Flora profitieren, muss noch 
untersucht werden. Zukünftige randomisierte multizentrische klinische Studien an einem 
repräsentativen Kollektiv werden, bei Berücksichtigung funktioneller sowie validierter 
klinischer Parameter, den Stellenwert der Präbiotika-Supplementation als prophylaktische und 
gegebenenfalls therapeutische Maßnahme beleuchten.  
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9. Appendix 
 
9.1 List of abbreviations  
Abbreviation
s 
 
% Percent 
∆ Delta or difference(s) 
# Number(s) 
~ Approximately 
< Less than 
> More than 
°C Degrees Celsius 
µg Microgram(s) 
µL Microliter(s) 
10E3 10 exponential 3 = 1000 
APC(s) Antigen presenting cell(s) 
APC-labelled Allophycocyanin labelled 
APGAR American Pediatric Gross Assessment Record 
B. bifidum Bifidobacterium bifidum 
BLG Beta lactoglobulin 
BMI Body mass index 
CB Cord blood 
CBMC Cord blood mononuclear cell(s) 
CD Cluster of differentiation  
CFU Colony forming unit(s) 
CKR Chemokine receptor(s) 
cm Centimetre(s) 
Con A Concavalin A 
DAPI  4',6-diamidino-2-phenylindol 
DC Dendritic cell(s) 
Der p1 Dermatophagoides pteronysinus 1 
DGGE Denaturing gel gradient electrophoresis 
DI Diversity index 
DPav Average degree of polymerization 
E. coli Escherichia coli 
e.g.  For example 
EDTA Ethylen diamine tetra acetate 
ELISA Enzyme-linked immune assay 
ELISPOT Enzyme-linked immunospot 
ESPGHAN European Society for Paediatric Gastroenterology Hepatology and Nutrition 
et al. And others 
F Fructose 
FACS Fluorescence activated cell sorting 
FISH Fluorescence in-situ hybridisation 
FITC-labelled Fluorescein isothiocyante labelled 
FOS Fructooligosaccharide(s) 
FSC Forward scatter 
g Gram(s) 
G Glucose 
GA Gestational age 
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GALT Gut associated lymphoid tissue 
G-CSF Granulocyte colony-stimulating factor 
GI  Gastrointestinal 
GIT Gastrointestinal tract 
GM-CSF Granulocyte-monocyte colony-stimulating factor 
GOS Galactooligosaccharide(s) 
h Hour(s) 
ICS Intracellular cytokine staining 
IFN-γ Interferon-gamma 
IgG1 Immune globulin G1 
IL-6 Interleukin-6 
IQR Interquartile range(s) 
kg Klilogram(s) 
L. acidophilus Lactobacillus acidophilus 
LGG Lactobacillus rhmnosus subspecies GG 
LH Lithium heparin 
LPS Lipopolysaccharid 
m2 Square meter(s) 
MCP-1 Monocyte chemoattractant protein-1 
MFI Mean fluorescence intensity 
mg Milligram(s) 
MHC Major histocompatibility complex 
min Minute(s) 
MIP-1ß Macrophage inflammatory protein-1 beta 
mL Millilitre(s) 
mRNA Messenger ribonucleic acid 
MWU Mann-Whitney U-test 
n Number(s) 
NDC Non-digestible carbohydrate(s) 
NH2-terminal Amino-terminal 
NK cell Natural killer cell 
nm Nanometer(s) 
NOD Nucleotide-oligomerization domain 
Nn T reg cells Natural naïve T regulatory cells 
NRBCs Nucleated red blood cells 
OF Oligofructose 
OS Oligosaccahride(s) 
OVA Ovalbumin 
P Significance value 
P1 Gate 1 (in FACS analysis) 
PAMPs Pathogen associated molecular patterns 
PBMC Peripheral blood mononuclear cell(s) 
PBS Phosphate buffered saline 
PC5-labelled Phycoerythrin-cyanin 5-labelled 
PCR Polymerase chain reaction 
PE-labelled Phycoerythrin-labelled 
pg Picogramm(s) 
PHA Phytohaemagglutinin 
PRR Pattern recognition receptor(s) 
Q1 Quadrant 1 (in FACS analysis) 
qPCR Quantitative polymerase chain reaction 
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RCT Randomized clinical trail(s) 
rDNA Ribosomal deoxyribonucleic acid 
RFLP Restriction fragment ploymorphism 
RNA Ribonucleic acid 
rpm  Rounds per minute 
S Svedberg 
S. cerevisae Saccharomyces cerevisae 
SCFA Short chain fatty acids 
SEB Staphylococcal enterotoxin B 
sec Second(s) 
SI Similarity index 
SSC Side scatter 
T reg cell T regulatory cell 
Tc cell T cytotoxic cell 
TCR T cell receptor 
TGF-β Transforming growth factor-beta 
TGGE  Temperature gel gradient electrophoresis 
Th cell T helper cell 
TLR Toll-like receptor 
TNF-α Tumor necrosis factor-alpha 
χ2 Pearson chi square test 
 
9.2 Index of figures 
 
Figure 1. Diagrammed representation of the human GIT showing approximate bacterial 
numbers in each region. 
 
Figure 2. Structure of inulin.  
 
Figure 3. T helper cell stimulation and Th1/Th2 cell polarization require three dentritic cell 
derived signals. 
 
Figure 4. Study design.   
 
Figure 5. Gating strategy for determining the frequency of CKR+ expressing CD4+ cells. 
 
Figure 6. Gating strategy for determining the frequency of CD4+CD25high T regulatory cells. 
 
Figure 7. Gating strategy for TLR+ expression on CD14+ monocytes. 
 
Figure 8. Flowchart of participant recruitment, sample collection and follow-up.  
 
Figure 9. Average vaginal pH values in the prebiotic and placebo group during the 
supplementation period. 
 
Figure 10. Average stool frequency per day in the prebiotic and placebo group during the 
supplementation period. 
 
Figure 11. PH values in maternal stool samples before study start (before) and after 
supplementation (after) in the prebiotic and placebo supplemented group. 
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Figure 12. Total bacterial counts in maternal stool samples before and after supplementation 
in the prebiotic and placebo group (determined by DAPI). 
 
Figure 13. Absolute numbers of bifidobacteria (bacteria/mL) in maternal stool samples before 
and after supplementation in the prebiotic and placebo supplemented group (determined by 
qPCR). 
 
Figure 14. Absolute numbers of lactobacilli (bacteria/mL) in maternal stool samples before 
and after supplementation in the prebiotic and placebo supplemented group (determined by 
qPCR). 
 
Figure 15. Percentages of bifidobacteria within total bacteria in maternal stool samples before 
and after supplementation in the prebiotic and the placebo group. 
 
Figure 16. Percentages of lactobacilli within total bacteria in maternal stool samples before 
and after supplementation in the prebiotic and the placebo group. 
 
Figure 17. PH values in neonatal stool samples from day 5, day 20 and day 182 in the 
prebiotic and placebo supplemented group. 
 
Figure 18. Total bacterial counts in neonatal stool samples from day 5, day 20 and day 182 in 
the prebiotic and placebo supplemented group (determined by DAPI). 
 
Figure 19. Absolute numbers of bifidobacteria (bacteria/mL) in neonatal stool samples from 
day 5, day 20 and day 182 in the prebiotic and placebo supplemented group (determined by 
qPCR). 
 
Figure 20. Absolute numbers of lactobacilli (bacteria/mL) in neonatal stool samples from day 
5, day 20 and day 182 in the prebiotic and placebo supplemented group (determined by 
qPCR). 
 
Figure 21. Percentages of bifidobacteria within total bacteria in neonatal stool samples from 
say 5, 20, and 182 in the prebiotic and the placebo supplemented group. 
 
Figure 22. Percentages of lactobacilli within number total bacteria in neonatal stool samples 
from day 5, day 20, and day 182 in the prebiotic and the placebo supplemented group. 
 
Figure 23. Frequency of CKR+ expressing cells within the CD4+ CB T cell population in the 
prebiotic and placebo group. 
 
Figure 24. Frequency of CKR+ expressing cells within the CD8+ CB T cell population in the 
prebiotic and placebo group. 
 
Figure 25. Frequency of CD25high expressing cells within different CD4+ subsets of CB T 
cells in the prebiotic and placebo group. 
 
Figure 26. MFI of TLR2+ and TLR4+ on CD14+ CB monocytes in the prebiotic and placebo 
group. 
 
Figure 27. Cytokine expression levels after stimulation of whole CB samples from the 
prebiotic and the placebo group with Der p1, BLG, LPS, OVA for 24 h. For IL-1ß, G-CSF, 
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IL-10, IFN-γ, TNF-α, GM-CSF and IL-4 concentrations are shown in pg/mL/10E3 leukocytes 
and for IL-2 in pg/mL/10E3 lymphocytes. 
 
Figure 28. Cytokine expression levels (pg/mL) after stimulation of whole CB samples from 
the prebiotic and the placebo group with Der p1, BLG, LPS, OVA for 24 h. For IL-6, IL-8, 
MIP-1ß and MCP-1 concentrations are shown in pg/mL/10E3 leukocytes. 
 
Figure 29. Cytokine expression levels (pg/mL) after stimulation of whole CB samples from 
the prebiotic and the placebo group with Con A and SEB for 24 h. For IL-1ß, G-CSF, IL-10, 
IFN-γ, TNF-α, GM-CSF and IL-4 concentrations are shown in pg/mL/10E3 leukocytes and 
for IL-2 in pg/mL/10E3 lymphocytes. 
 
Figure 30. Cytokine expression levels (pg/mL) after stimulation of whole CB samples from 
the prebiotic and the placebo group with Con A and SEB for 24 h. For IL-6, IL-8, MIP-1ß and 
MCP-1 concentrations are shown in pg/mL/10E3 leukocytes. 
 
9.3. Index of tables 
 
Table 1. Summary of some chemokine receptors and their known ligands.  
 
Table 2. Composition of the prebiotic and the placebo supplement (per 100 mL). 
 
Table 3. Instruments and software. 
 
Table 4. Consumables. 
 
Table 5. Reagents. 
 
Table 6. Antibodies used for flow cytometric staining. 
 
Table 7. Antibody combinations used for CB staining. 
 
Table 8. Baseline characteristics of the study group. 
 
Table 9. Study population at delivery.  
 
Table 10. Feeding habits, atopic eczema and antibiotics in the first 6 months of life.  
 
Table 11. Percentage of mothers positive for specific bifidobacterial and lactobacilli species.  
 
Table 12. Percentage of neonates positive for specific bifidobacterial and lactobacilli species. 
 
Table 13. Bifidobacterial and lactobacilli diversity indices in mothers receiving prebiotic or 
placebo supplementation and their infants. 
 
Table 14. Infant-mother correlations for specific bifidobacterial and lactobacilli species (as 
determined by qPCR) in mothers receiving prebiotic or placebo supplementation.  
 
Table 15. Infant-mother bifidobacterial, lactobacilli and bifidobacterial plus lactobacilli 
similarity indices (%) obtained for samples taken from the mothers after delivery and from the 
infants at day 5, day 20 and day 182 in the prebiotic and placebo supplemented group.  
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Table 16. Frequency of CD45RA+ and CD45RO+ expressing cells within the CD4+ and CD8+ 
CB T cell population in the prebiotic and placebo group. 
 
Table 17. Th1:Th2 ratio on CD4+ and CD8+ CB T cells in the prebiotic and placebo group. 
 
9.4 Primers and probes used for the duplex 5′ nuclease assays  
 
Target Primer 
or probe 
Sequence  
(5′ → 3′) 
Tm 
°C 
% GC BLAST 
identification 
no. or reference 
Amplicon 
length 
(bp) 
B. adolescentis F_adol_IS ATA GTG GAC GCG 
AGC AAG AGA 
59 52 1015335678-6465-
18906 
71 
 R_adol_IS TTG AAG AGT TTG 
GCG AAA TCG 
59 43 1015335740-7519-
1624 
 
 P_adol_IS CTG AAA GAA CGT 
TTC TTT TTa 
69 30 1015335863-95222-
17207 
 
B. angulatum F_angul_IS TGG TGG TTT GAG 
AAC TGG ATA GTG 
59 46 1015336044-12581-
14600 
117 
 R_angul_I
S 
TCG ACG AAC AAC 
AAT AAA CAA AAC 
A 
59 32 1015336147-14351-
29932 
 
 P_angul_IS AAG GCC AAA GCC 
TC 
70 57 1015488648-5575-
2104 
 
B. bifidum F_bif_IS GTT GAT TTC GCC 
GGA CTC TTC 
60 52 1015336612-
215666-12828 
105 
 R_bif_IS GCA AGC CTA TCG 
CGC AAA 
60 56 1015336668-22451-
30731 
 
 P_bif_IS AAC TCC GCT GGC 
AAC A 
70 56 1015336773-24053-
3416 
 
B. breve F_breve_IS GTG GTG GCT TGA 
GAA CTG GAT AG 
59 52 1015243936-11550-
20833 
118 
 R_breve_I
S 
CAA AAC GAT CGA 
AAC AAA CAC TAA 
A 
58 32 1015244110-13595-
29514 
 
 P_breve_IS TGA TTC CTC GTT 
CTT GCT GT 
69 45 1015244238-15062-
16853 
 
B. catenulatum F_cate_IS GTG GAC GCG AGC 
AAT GC 
58 65 1015335268-99-
20718 
67 
 R_cate_IS AAT AGA GCC TGG 
CGA AAT CG 
58 50 1015335364-1571-
12175 
 
 P_cate_IS AAG CAA ACG ATG 
ACA TCA 
68 39 1015335455-2899-
17859 
 
B. dentium F_dent_IS CCG CCA CCC ACA 
GTC T 
59 71 1015399643-15856-
19947 
150 
 R_dent_IS AGC AAA GGG 
AAA CAC CAT GTT 
T 
59 41 1015399751-16991-
11210 
 
 P_dent_IS ACG CGT CCA ACG 
GA 
70 64 1015399833-18158-
5198 
 
B. infantis F_inf_IS CGC GAG CAA AAC 
AAT GGT Ta 
58 47 1037961234-06371-
14364 
76 
 R_inf_IS AAC GAT CGA AAC 
GAA CAA TAG AGT 
T 
58 36 1037961263-06691-
25461 
 
 P_inf_IS TTC GAA ATC AAC 
AGC AAA Aa 
69 32 1037961294-06967-
17477 
 
B. longum F_long_IS TGG AAG ACG TCG 
TTG GCT TT 
59 50 1015323391-27595-
22257 
109 
 R_long_IS ATC GCG CCA GGC 58 56 1015323469-28673-  
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AAA Aa 23147 
 P_long_IS CGC ACC CAC CGC 
A 
68 77 1015488566-4529-
13934 
 
All bifidobacteria F_allbif_IS GGG ATG CTG GTG 
TGG AAG AGA 
60 57 1015399960-19603-
31240 
231a 
 R_allbif_IS TGC TCG CGT CCA 
CTA TCC AGT 
60 57 1015400076-20827-
17418 
 
 P_allbif_IS TCA AAC CAC CAC 
GCG CCA 
70 61 1015400166-21749-
18424 
 
L. acidophilus F_acid_IS GAA AGA GCC 
CAA ACC AAG TGA 
TT 
59 43 1089017502-26171-
202965955840 
85 
 R_acid_IS CTT CCC AGA TAA 
TTC AAC TAT CGC 
TTA 
59 37 1089017571-27139-
52545094772 
 
 P_acid_IS TAC CAC TTT GCA 
GTC CTA CA 
70 45 1089017717-29310-
154296055415 
 
L. casei F_case_IS CTA TAA GTA AGC 
TTT GAT CCG GAG 
ATT T 
59 36 1037022798-
023495-2136 
132 
 R_case_IS CTT CCT GCG GGT 
ACT GAG ATG T 
59 55 1037022917-
024843-29627 
 
 P_case_IS ACA AGC TAT GAA 
TTC ACT TGC 
70 38 1037022752-
023005-20772 
 
L. delbrueckii F_delb_IS CAC TTG TAC GTT 
GAA AAC TGA ATA 
TCT TAAa 
58 30 1089018504-4206-
64529811906 
94 
 R_delb_IS CGA ACT CTC TCG 
GTC GCT TT 
58 55 1089018475-6841-
166657768151 
 
 P_delb_IS CCG AGA ATC ATT 
GAG ATC 
68 44 1089018437-6309-
163988227498 
 
L. fermentum F_ferm_IS AAC CGA GAA CAC 
CGC GTT AT 
58 50 1036676682-09669-
23287 
88 
 R_ferm_IS ACT TAA CCT TAC 
TGA TCG TAG ATC 
AGT CA 
58 38 1036676709-
010209-2351 
 
 P_ferm_IS TAA TCG CAT ACT 
CAA CTA A 
68 32 1036676736-
010547-20717 
 
L. paracasei F_paca_IS ACA TCA GTG TAT 
TGC TTG TCA GTG 
AAT AC 
60 38 1038306417-
016220-23561 
80 
 R_paca_IS CCT GCG GGT ACT 
GAG ATG TTT C 
60 55 1038306445-
016796-3050 
 
 P_paca_IS TGC CGC CGG CCA 
G 
70 85 1038306524-
018375-2626 
 
L. plantarum F_plan_IS TGG ATC ACC TCC 
TTT CTA AGG AAT 
58 42 1038305707-03107-
18756 
144 
 R_plan_IS TGT TCT CGG TTT 
CAT TAT GAA AAA 
ATAa 
58 26 1038305742-04177-
12861 
 
 P_plan_IS ACA TTC TTC GAA 
ACT TTG T 
68 32 1038305778-04682-
12880 
 
L. reuteri F_reut_IS ACC GAG AAC ACC 
GCG TTA TTT 
59 48 1089025339-29395-
129280047216 
93 
 R_reut_IS CAT AAC TTA ACC 
TAA ACA ATC AAA 
GAT TGT CT 
59 28 1089025385-30347-
37558232754 
 
 P_reut_IS ATC GCT AAC TCA 
ATT AAT 
69 28 1089025413-30287-
26112845854 
 
L. rhamnosus F_rham_IS CGG CTG GAT CAC 
CTC CTT T 
59 58 1023708254-09591-
2284 
97 
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 R_rham_IS GCT TGA GGG TAA 
TCC CCT CAA 
59 52 1023708352-
010389-16127 
 
 P_rham_IS CCT GCA CAC ACG 
AAA 
69 55 1023708453-
011313-6655 
 
Lactobacillus 
spp. 
F_alllact_I
S 
TGG ATG CCT TGG 
CAC TAG GA 
58 55 1024485925-
024664-30598 
92 
 R_alllact_I
S 
AAA TCT CCG GAT 
CAA AGC TTA CTT 
AT 
58 35 1024478788-
024701-16287 
 
 P_alllact_I
S 
TAT TAG TTC CGT 
CCT TCA TC 
68 40 1024478009-
017753-28422 
 
All bacteria F_eub TCC TAC GGG AGG 
CAG CAG T 
59  Reference [160] 466a 
 R_eub GGA CTA CCA GGG 
TAT CTA ATC CTG 
TT 
58    
 P_eub CGT ATT ACC GCG 
GCT GCT GGC AC 
70    
aIn these cases, concessions to the probe and primer design had to be made (more than three 
consecutive nucleotides are the same or amplicon length is greater then 150 bp). According to 
Haarman et al. [126, 127]. 
  APPENDIX 
 104
9.5 Study sheets 
 
9.5.1 Parent information sheet 
 
PREBIOTICS AND THEIR INFLUENCE ON THE IMMUNE SYSTEM OF PREGNANT 
WOMEN AND THEIR NEWBORNS 
 
 
Dear Parents, 
 
During the last few years allergic diseases have become more and more prevalent among 
children. Although many investigations indicate that environmental influences during 
pregnancy are relevant for the development of allergies in later life, the exact reasons for this 
increase are still unclear. Among other factors, the predominance of certain gut bacteria like 
lactobacilli and bifidobacteria are supposed to have protective effects. With this letter we 
want to inform you about a study, which examines the influence of prebiotics on the gut 
microbiota and the immune system of pregnant women and their newborns.  
This study is carried out at the Children’s Hospital of the Ludwig-Maximilians-University of 
Munich, Department of Metabolic Disease and Nutrition, “Dr. von Haunerschen Kinderspital” 
under the supervision of Prof. Dr. Berthold V.Koletzko and Dr. Susanne Krauss-Etschmann. 
Prebiotics are naturally occurring food carbohydrates, which we cannot digest but which 
specifically stimulate the growth of bifidobacteria and lactobacilli. These bacteria 
predominate in the gut of healthy breast fed infants and are supposed to protect against 
various enteric infections. In addition, lactobacilli protect the vagina from infections with 
fungi and other harmful bacteria. One of these harmful bacteria are streptococci, which cause 
almost no symptoms in pregnant women, but can lead to life threatening infections in 
newborns. According to newer results, it appears that the consumption of certain lactobacilli 
during infancy can reduce the occurrence of allergies in the first two years by almost 50%. 
Therefore, our study wants to examine the influence of dietary long-term supplementation 
with prebiotics during pregnancy on the composition of the maternal and neonatal gut 
microbiota. We also want to assess whether prebiotic supplementation stabilizes the vaginal 
colonization with lactobacilli and thereby reduces the incidence of bacterial vaginosis. 
Furthermore, we want to analyse whether prebiotics can influence the immune system of 
newborns and lead to a reduction of allergy incidence. 
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If you are interested in participating in this study, we would like to ask you for your 
cooperation: 
We will provide you with a prebiotic or maltodextrin supplementation in form of sachets. You 
will be consuming three sachets per day from the 25th week of gestation until delivery. Before 
study begin we will collect two stool samples form you. Additional two samples will be 
collected towards study end (shortly before delivery). We also ask you to weekly check your 
vaginal pH with the help of CarePlan VpH test gloves (which you will be receiving from us). 
Additionally, we ask you for a singular blood sample of 10 mL, which will be taken from you 
during the routine medical check-up at delivery.  
Furthermore, placental venous cord blood will be collected at delivery to assess possible 
effects on the neonatal immune system. Later on, we will ask you for stool samples from your 
child at the 5th and 20th day of life. Serious risks for you and your child exist at no time point 
of the study. According to the regulations, however, a study participant insurance was signed 
(Aon Nederland V 001100031366). The data from the examinations will be saved 
electronically. Within the frame of the corresponding regulatory instructions, only the 
examining doctors, as well as authorized collaborators will have access to the confidential 
data, in which you and your child are mentioned by name. These persons are under 
professional discretion and are obliged to data protection. Anonymous data will only be 
passed on for statistical and scientific reasons.  
Your participation in the study is voluntarily. 
You can of course withdraw your participation agreement at any time point of the study 
without any reasons and disadvantages for you and your child. Questions about the content 
and subject of the study will be answered by Dr. Susanne Krauss-Etschmann and members of 
the study team at any time point (telephone: 089/51607706). 
Your advantage: 
During the study we will inform you about your and your child’s stool sample results. If you 
decide to take part in the study, we kindly ask you to declare with your signature that you 
have been informed about the content and the course of the study and that you agree to 
participate. 
Thank you very much! 
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9.5.2 Inclusion & exclusion criteria sheet 
 
INCLUSION & EXCLUSION CRITERIA  
Inclusion criteria: 
• Healthy pregnant woman > 18 and < 40 years  
• Signed informed consent 
• No acute illness  
• No treatment with antibiotics 
• No regular consumption of probiotic or prebiotic supplements 
• Planned delivery at the Obstetrics Hospital or the Department of Obstetrics & Gynaecology  
  of the Ludwig-Maximilians-University of  Munich 
• Planned vaginal delivery  
 
Exclusion criteria: 
• Gestational age above the 24th week at enrolment 
• Intention to donate cord blood stem cells 
• Acute illness or chronic inflammatory bowel disease (Crohn’s disease, ulcerative colitis or  
   gestational diabetes)  
• Allergies are not an exclusion criterion!!!!! 
• Consumption of anti-inflammatory drugs (cortisone, acetylsalicylic acid, non-steroidal anti-   
  inflammatory drugs) 
• Planned caesarean section 
• Perinatal asphyxia (5 min APGAR < 7.0; cord blood pH < 7.2) 
• Clinical or laboratory signs for a neonatal or maternal infection at delivery  
• Obvious malformation of the newborn 
• Interruption of the supplementation for longer than two days and more than two times 
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9.5.3 Informed consent sheet 
 
INFORMED CONSENT  
PREBIOTICS AND THEIR INFLUENCE ON THE IMMUNE SYSTEM OF PREGNANT 
WOMEN AND THEIR NEWBORNS - A CLINICAL INTERVENTION STUDY 
Surname:        ______________________________________________________________ 
First name:     ______________________________________________________________ 
Date of birth:  ______________________________________________________________ 
Code:             ______________________________________________________________ 
I here with confirm that the study conditions were completely explained to me. 
A copy of the enclosed form, containing the study conditions was given to me.  
All questions were answered to my satisfaction. Possible risks and disadvantages were 
explained to me. I know that I can now and at any other future time point ask questions 
considering the study and the examination results.  
I consent that my health data are recorded within the scope of the clinical examination, that 
they can be viewed by authorized representatives of the sponsors of the clinical study, the 
monitoring authority or the federal authority and that they can – as far as the reference to my 
person is not recognizable from these data – be passed on to the sponsors of the clinical study 
and the above mentioned authorities for inspection reasons. I was assured that my and my 
child’s data remain confidential at any time point. 
Information concerning my or my child’s identity will not be passed on or printed. 
I know that I and my child can withdraw from the study at any time point. 
I further understand that - if the study is not completed or if I withdraw from the study at any 
time point - the quality of the medical treatment for me and my baby at the Obstetrics 
Hospital of the Ludwig-Maximilians-University of Munich (I. UFK) will not be affected. 
 
I agree to take part:     Munich, the   _____________________ 
 
____________________________               ________________________________ 
Signature of the participant                            Signature of the informing staff 
  APPENDIX 
 108
9.5.4 Instruction sheet 
 
INSTRUCTIONS 
Stool samples:  
In your envelope you will find two tubes containing spatula containers for stool sampling. 
Please use the spatula to collect a small amount of stool (~ size of a pea) and close the 
containers properly. Please label the tube with your name and birth day. Your data will be 
coded later on. Please store the tube immediately after sample withdrawal in the freezer.  
There are definitely no hygienic risks with the correct withdrawal technique. 
Please inform us as soon as you have collected the sample by calling: 089 / 5160 – 7706 or 
089 / 5160 – 7796. You can also leave a message on the answering machine. We will then 
come and collect the samples within 24 hours. 
 
Questionnaires: 
In the envelope you will find a questionnaire. Please fill out the questionnaire (1) as 
complete as possible and bring it with you to the next check-up appointment. There is 
evidence from many studies that there is a connection between the bacteriological 
colonization of the gut and the hygienic conditions or the current lifestyle in the early 
childhood. Furthermore, diseases and medication can be of some relevance. The asked 
questions are important and are based on medical examinations, which have already been 
performed. 
 
General information:  
If you have any further questions, e.g. concerning the questionnaire or the sample withdrawal, 
please ask us at your next check up appointment or directly call us at any time point. We 
assure that your personal data will be deleted, so that later on an assignment to the sample will 
not be possible. 
 
Thank you very much for your cooperation! 
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9.6 Study questionnaires 
 
9.6.1 Questionnaire 1: Allergies  
 
ALLERGY QUESTIONNAIRE (Q1) 
 
Name:   
Code & ID:  Mother Father 
Nr. Questions about the parents Yes No Yes No 
1. Do you or did you ever have asthma?     
2. Has this been confirmed by a doctor?     
3. Did you have an asthma attack in the last 12 month?     
4. Do you take any medicine (inhalation, spray, pills) 
against asthma at the moment? If yes, which? 
________________________________ 
 
    
5. Do you or did you have hay fever, rhinitis or allergic 
conjunctivitis? 
    
6. Do you or did you suffer - without having a cold - 
from a congested or running nose and/or swollen, 
itchy eyes and this regularly in the spring and 
summer time or almost every time you deal with 
specific fur or feather carrying animals? 
    
7. Do you or did you ever suffer from neurodermatitis 
(also called endogenous eczema or atopic 
dermatitis)? 
    
8. Do or did you have hives also called urticaria, with 
wheals like after a nettle contact/and or swelling of 
the lips and eyes? 
    
9. Do you regularly react allergic to certain foods 
(urticaria, worsening of eczema, nausea, vomiting, 
diarrhoea, asthma)? 
    
10. Do you regularly take medicine? If yes, which? 
_____________________________________ 
_____________________________________ 
 
    
11. Do you smoke?  
If yes how many cigarettes per day? ________ 
 
    
 The following questions are referred to siblings (not 
half brothers and sisters) of your baby? 
    
12. Does your baby have siblings (no half brothers and 
sisters)?  
If you have answered question 12 with no, please 
omit the following questions. If you have answered 
question 12 with yes, please answer the following 
questions:  
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Sibling 1 Sibling 2 
 Questions about the siblings: Yes No Yes No 
13. Did your child ever have asthma?     
14. Did your child ever have hay fever?     
15. Did your child have sneezing attacks, a running, 
congested, or itchy nose although he/she was not 
suffering from a cold? 
    
16. Did your child ever have an itchy skin rash, which 
was more or less severe over the last 6 months? 
    
17. Did your child ever have neurodermatitis? (also 
called endogenous eczema or atopic dermatitis)? 
    
18. Does your child regularly suffer from certain food 
allergies (urticaria, worsening of eczema, nausea, 
vomiting, diarrhoea, asthma)? 
    
 
Thank you very much for your cooperation! 
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9.6.2 Questionnaire 2: Stool frequency, consistency & regurgitation 
 
STOOL FREQUENCY, CONSISTENCY & REGURGITATION QUESTIONNAIRE (Q2) 
Name:  
Code & ID:  
Please weekly fill out the following table: enter how often you suffered from regurgitation 
as well as your daily average stool frequency and consistency according to the codes below.
Gestational 
age 
Regurgitation  Stool frequency Stool consistency 
25th  week    
26th  week    
27th  week    
28th  week    
29th  week    
30th  week    
31st  week    
32nd  week    
33rd  week    
34th  week    
35th  week    
36th  week    
37th  week    
38th  week    
39th week    
40th  week    
    
    
 1 = no regurgitation  
2 = regurgitation good to bear  
3 = regurgitation just to bear   
4 = regurgitation almost not to bear  
5 = regurgitation unbearable 
average per day 1 = no stool 
2 = very hard and painful stool 
3 = hard stool 
4 = soft and formed stool 
5 = soft and non-formed stool   
6 = diarrhoea  
 
Thank you very much for your cooperation! 
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9.6.3 Questionnaire 3: Vaginal pH 
 
VAGINAL PH QUESTIONNAIRE (Q3) 
Name:  
Code & ID:  
Please measure your vaginal pH with the enclosed CarePlan VpH test gloves once a week 
and enter the vaginal pH value into the table with the help of the colour scale below. 
Gestational age Vaginal pH 
25th  week  
26th  week  
27th  week  
28th  week  
29th  week  
30th  week  
31st  week  
32nd  week  
33rd  week  
34th  week  
35th  week  
36th  week  
37th  week  
38th  week  
39th  week  
40th  week  
  
  
A disturbance of the vaginal microbiota is often accompanied by infections, which can 
increase the risk of early birth or abortion. In many cases measuring vaginal pH allows an 
early recognition of a disturbed flora. The weekly control of your vaginal pH during 
pregnancy can improve your chances for an early detection of an infection and a timely 
doctoral supervision. You should visit the doctor if the pH value is above 4.4. 
 
 
Colour scale for reading the pH-values: 
 
 
 
 
 
 
 
NORMAL 
4.0 4.4 4.7 5.0 5.3 5.5 5.8 7.0
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9.6.4 Questionnaire 4: Compliance & tolerance 
 
COMPLIANCE & TOLERANCE QUESTIONNAIRE (Q4) 
Dear study participant! 
First of all we would like to thank you for taking part in this study. 
The purpose of the following questionnaire is to find out how good pregnant women tolerate 
the supplementation. We therefore ask you to read the following questions carefully before 
answering them. Important: Most questions can be answered at the end of your pregnancy. 
Please note that the tables with the questions concerning regurgitation or reflux, stool 
frequency and consistency (questionnaire 2) as well as vaginal pH (questionnaire 3) must be 
answered weekly. 
Name: ____________________________________________________________________   
Code/ID: ________________________________  Date of birth: _____________________ 
 
1. What is your martial status?      
 unmarried          
  married          
2. What is your nationality? ____________________________________________________ 
3. If you are not from Germany, how long have you been living here? ______________years 
4. What is your highest school education?  
 No school education        
 CSE          
 Secondary school or similar certificate     
 Technical college        
 General qualification for university      
5. What is your highest job qualification? 
 No job qualification        
 Finished apprenticeship       
 Master craftsman’s certificate       
 Vocational school degree       
 Technical college degree       
 University degree        
6. If you had stool irregularities, of what kind were they? 
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___________________________________________________________________________
___________________________________________________________________________
7. Did you stop taking the sachets for longer than 2 days? 
 Never          
 Once          
 Twice          
 More than twice        
8. How good did you tolerate the sachets? 
 Very good         
 Good          
 Not so good         
 Not at all         
9. If you did not tolerate the sachets so good or if you did not tolerate them at all: 
     Why was the tolerance not so good? What kind of problems or complaints did you have? 
___________________________________________________________________________
___________________________________________________________________________ 
10. How intensive were your complaints?  
 I had no complaints        
 Good to bear         
 Bearable        
 Almost unbearable        
 Unbearable         
11. If you had complaints, how long did these usually last? 
 Only short         
 Up to one hour         
 Several hours         
 The whole day         
10. Did you stop taking the sachets before the end of your pregnancy? 
 Yes          
 No          
13. If you stopped taking the sachets, what were the reasons? 
___________________________________________________________________________ 
Thank you very much for your cooperation! 
 
  APPENDIX 
 115
9.6.5 Questionnaire 5: Follow-up interview  
 
FOLLOW-UP INTERVIEW (Q5 SHORT VERSION) 
 
Name: ____________________________________________________________________ 
Code & ID: ______________________________  Date of birth: _____________________ 
 
Interviewer ID: __________________________   Date of interview:__________________ 
 
1. What is the name of your  child? _____________  
2. When was your child born? _________________ 
3. What kind of milk did your child get in the first 3 three days after birth? 
  Breast milk 
  Formulae milk 
  Others: ________________________ 
4. What kind of milk did your child get in the first 6 months? 
  Breast milk 
  Formulae milk 
  Others: ________________________ 
5. Are you still breast feeding at the moment? 
  Yes, exclusively 
  Yes, but not exclusively 
  No 
6. Have you started giving solid food to your child?  
  Yes  
  No 
7. If yes, what kind of solid food did you give your child? ___________________________ 
8. How old was you child when your started giving solid food? _______________________ 
9. In the last 6 months, did your child ever suffer from 
  Cold 
  Fever 
  Cough 
  Atopic eczema 
  Food allergy 
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10. Did your child receive antibiotics in the first 3 weeks after birth? 
  Yes               
  No 
11. If yes, which antibiotics did your child get? ____________________________________ 
Why?  ______________and for how long? ______________and how often? _____________ 
12. Did your child receive antibiotics in the last 5 months? 
  Yes 
  No 
13. If yes, which antibiotics did your child get ?____________________________________ 
Why?  ______________and for how long? ______________and how often? _____________ 
 
Thank you very much for your cooperation! 
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